UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 17, 2014 (October 14, 2014)


LUMINEX CORPORATION
(Exact name of registrant as specified in its charter)


DELAWARE
 
000-30109
 
74-2747608
(State or other jurisdiction of incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No.)

12212 TECHNOLOGY BLVD., AUSTIN, TEXAS
 
78727
(Address of principal executive offices)
 
(Zip Code)


Registrant’s telephone number, including area code: (512) 219-8020


N/A
(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
 
o
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
 
o
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
 
o
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))







Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Retirement of Patrick J. Balthrop, Sr .
On October 14, 2014, Patrick J. Balthrop, Sr. resigned from his positions as President and Chief Executive Officer and as a director of Luminex Corporation (the “Company”), in each case effective as of 5:00 p.m. (CDT) on that date. The retirement of Mr. Balthrop is not due to any disagreement with the Company or any matters relating to the Company’s operations, policies or practices.
Concurrently with Mr. Balthrop’s retirement, the Company and Mr. Balthrop entered into a consulting agreement dated October 14, 2014 (the “Consulting Agreement”), the term of such agreement to commence upon Mr. Balthrop’s retirement from the Company and continue for a period of six months (the “Consulting Term”). Pursuant to the Consulting Agreement, Mr. Balthrop will advise the Company’s new Chief Executive Officer and Board of Directors (the “Board”) on strategic matters and other transitional and consulting services to be reasonably requested and authorized by the Company’s new Chief Executive Officer from time to time. As compensation, Mr. Balthrop will be paid at a monthly rate of $58,333. Mr. Balthrop, subject to certification of performance metrics, will also be entitled to a prorated performance bonus for fiscal year 2014 (paid in the ordinary course with other Management Incentive Plan participants) and will continue to vest in option and restricted stock grants while providing services to the Company during the Consulting Term. Mr. Balthrop’s right to receive the foregoing is subject to, among other obligations, his execution of a general release of claims against the Company. In addition, the Consulting Agreement contains certain non-competition, non-solicitation and confidentiality provisions.
The above description of the Consulting Agreement does not purport to be complete and is qualified in its entirety by reference to the Consulting Agreement itself, a copy of which is attached to this report as Exhibit 10.1, and is incorporated herein in its entirety by reference.

Appointment of Nachum “Homi” Shamir as President and Chief Executive Officer and Director .

On October 14, 2014, the appointment of Nachum "Homi" Shamir as President and Chief Executive Officer of the Company became effective. In connection with Mr. Shamir’s appointment by the Board as President and Chief Executive Officer, the Board also appointed Mr. Shamir to serve as a Class I director of the Company until the Company’s annual meeting of stockholders to be held in 2016. Mr. Shamir will serve on the Executive Committee and the Strategy and Development Committee of the Board.

Biographical and Other Information. Prior to joining the Company, Mr. Shamir, age 60, served as President and Chief Executive Officer and director of Given Imaging Ltd., a developer, manufacturer and marketer of diagnostic products for the visualization and detection of disorders of the gastrointestinal tract, from April 2006 to 2014.   Mr. Shamir served as Corporate Vice President of Eastman Kodak Company, a technology company focusing on imaging solutions and services for businesses, from 2004 to 2006 and as the President of Eastman Kodak´s Transaction and Industrial Solutions Group from 2005 to 2006, which includes several business units, including Kodak Versamark, Inc. (whose operations were previously those of Scitex Digital Printing Inc.) of which Mr. Shamir was President and Chief Executive Officer. From June 2003 to January 2004, Mr. Shamir served as the President and Chief Executive Officer of Scitex Corporation Ltd., a multinational public company which specialized in producing products, systems and equipment for the graphics design, printing and publishing markets through its various operating units. From January 2001 to January 2004, Mr. Shamir served as the President and Chief Executive Officer of Scitex Digital Printing Inc., a subsidiary of Scitex Corporation Ltd., having previously served as its Chief Operating Officer since July 2000. Prior thereto, Mr. Shamir was Managing Director and General Manager of Scitex Digital Printing (Asia Pacific) Pte Ltd., from the incorporation of this Singapore-based company in 1994. From 1993 until 1994 Mr. Shamir was with the Hong Kong based Scitex Asia Pacific (H.K.) Ltd. Before joining Scitex, Mr. Shamir held senior management positions at various international companies mainly in the Asia Pacific regions. Mr. Shamir currently serves on the board of directors of Invendo Medical GmbH, a manufacturer and distributor of a single use and computer-assisted colonoscopy system. Mr. Shamir holds a Bachelor of Science from the Hebrew University of Jerusalem and a Masters of Public Administration from Harvard University.
There are no arrangements or understandings between Mr. Shamir and any other person pursuant to which Mr. Shamir was appointed as an officer and a director of the Company. There are no family relationships between Mr. Shamir and any director or executive officer of the Company. There are no transactions between Mr. Shamir and the Company that would be reportable under Item 404(a) of Regulation S-K.





Employment Agreement. In connection with Mr. Shamir’s appointment as President and Chief Executive Officer and a director of the Company, Mr. Shamir and the Company entered into an employment agreement dated October 14, 2014 (the “Employment Agreement”), pursuant to which his employment commenced at 5:00 p.m. (CDT) on that date and he was appointed as President and Chief Executive Officer. The Employment Agreement has a two year term, ending October 14, 2016, subject to automatic one year renewals unless either party gives notice of intent not to renew.
The Employment Agreement provides that Mr. Shamir will receive an initial base salary at the annual rate of $600,000 and a target bonus opportunity of 100% of his annual base salary. Pursuant to the Employment Agreement, Mr. Shamir was also awarded (i) an option to purchase two hundred and fifty thousand (250,000) shares of the Company’s common stock and (ii) one hundred thousand (100,000) shares of the Company’s restricted common stock, each under and subject to the terms of the Company’s Second Amended and Restated 2006 Equity Incentive Plan. The options and shares of restricted common stock are subject to the applicable equity award agreements, which provide that the options and shares of restricted stock will each vest over four years and that the options will be for a term of seven years. The exercise price of the options is $21.10 (the closing market price on the date of grant). The Employment Agreement also provides Mr. Shamir with certain benefits, such as reimbursement of expenses, vacation, medical, life and disability insurance, relocation expenses and temporary housing.

The Employment Agreement provides for severance payments where Mr. Shamir is terminated without “cause” (including the Company’s failure to renew the Employment Agreement) or as a result of incapacity or death, or if Mr. Shamir resigns upon a “constructive termination.” “Constructive termination” generally means certain demotions in responsibilities or title, decreases in compensation, the Company’s material breach of the Employment Agreement and/or relocation requirements, while “cause” means failure to perform the duties outlined in the Employment Agreement, conduct likely to cause material injury to the Company, indictment or conviction of a felony or a criminal act involving moral turpitude, violation of a Company policy or a breach of the Employment Agreement, in each case to the extent not cured (if curable) within thirty (30) days’ notice of such event.

Severance generally consists of (a) an amount equal to Mr. Shamir’s base salary at the highest rate in effect for the six month period prior to termination or the amount of base salary that would have been paid over the remainder of the then-current term (if greater) and (b) the prior year’s bonus amount. If the termination occurs other than for cause or voluntary termination, Mr. Shamir is entitled to additional severance in an amount equal to the pro-rated portion of the current-year bonus to the extent the performance measures are achieved. Severance also includes welfare benefits for a period of twelve months following termination and a lump sum amount equal to the Company’s annual cost for Mr. Shamir’s disability and life insurance in effect on the date of termination as well as the Company’s prior year 401(k) plan contribution for Mr. Shamir.

Except for the lump sum amount described above, the severance payments are paid in semi-monthly installments for a period of 12 months following the date of termination. Additionally, the Employment Agreement provides that in the event the payment of any severance amounts payable pursuant to the Employment Agreement within six months of the date of Mr. Shamir’s termination of employment would cause Mr. Shamir to incur any additional tax under Section 409A of the Internal Revenue Code of 1986, as amended, then payment of such amounts will be delayed until the date that is six months following Mr. Shamir’s termination date. Receipt of any severance payments or benefits is conditioned upon Mr. Shamir’s release of all claims against the Company and its officers and directors.
The Employment Agreement provides for acceleration of vesting, or lapse of restrictions, of equity awards held by Mr. Shamir in connection with a change in control of the Company. In addition, in the event Mr. Shamir’s employment is terminated by the Company within six months of the occurrence of a change in control of the Company, in lieu of the severance compensation described above, Luminex must pay Mr. Shamir’s prior year’s bonus amount and Mr. Shamir’s base salary at the highest rate in effect for the six months immediately prior to the change in control through the date of termination, in lump sum within three business days of termination. Mr. Shamir would also be entitled to an amount equal to the pro-rated portion of the current-year bonus to the extent the performance measures are achieved.
The Employment Agreement contains provisions governing the nondisclosure and nonuse of confidential information of the Company, provisions requiring the assignment of certain intellectual property rights to the Company, and non-competition and non-solicitation restrictive covenants which remain in existence for two years following Mr. Shamir’s termination.
The Company and Mr. Shamir also entered into the Company’s standard director and officer indemnification agreement, the form of which was filed with the Securities and Exchange Commission (the “SEC”) as Exhibit 10.1 to the Company’s Current Report on Form 8-K on September 16, 2008.





The above description of the Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the Employment Agreement itself, a copy of which is attached to this report as Exhibit 10.2, and is incorporated herein in its entirety by reference.

Item 7.01. Regulation FD Disclosure.
On October 15, 2014, the Company issued a press release announcing the appointment of Mr. Shamir and the retirement of Mr. Balthrop. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference.
Limitation on Incorporation by Reference. The information furnished in this Item 7.01, including the press release attached hereto as Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Cautionary Note Regarding Forward-Looking Statements. Except for historical information contained in the press release attached as Exhibit 99.1 hereto, the press release contains forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. Please refer to the cautionary notes in the press release regarding these forward-looking statements.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.
 
Description
10.1
 
Consulting Agreement, dated October 14, 2014, between Luminex Corporation and Patrick J. Balthrop, Sr.
10.2
 
Employment Agreement, dated October 14, 2014, between Luminex Corporation and Nachum Shamir
99.1
 
Press Release issued by Luminex Corporation dated October 15, 2014






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 17, 2014
LUMINEX CORPORATION
 
 
 
 
By:  
/s/ Harriss T. Currie  
 
 
Name:  
Harriss T. Currie 
 
 
Title:  
Chief Financial Officer, Senior Vice President of Finance 






EXHIBIT INDEX


Exhibit No.
 
Description
10.1
 
Consulting Agreement, dated October 14, 2014, between Luminex Corporation and Patrick J. Balthrop, Sr.
10.2
 
Employment Agreement, dated October 14, 2014, between Luminex Corporation and Nachum Shamir
99.1
 
Press Release issued by Luminex Corporation dated October 15, 2014




Exhibit 10.1


CONSULTING AGREEMENT


This Consulting Agreement (the “Agreement”) is made and entered into as of this 14 th day of October, 2014, between Luminex Corporation (the “Company”), and Patrick J. Balthrop, Sr. (“Balthrop”).
 
WHEREAS , Balthrop has been employed as the President and Chief Executive Officer of the Company;
WHEREAS , Balthrop has indicated his desire to retire and leave all officer and director positions with the Company, effective as of the date hereof;
WHEREAS , the Company desires to retain Balthrop, and Balthrop desires to serve, as a consultant to the Company for a period of time following his retirement in exchange for certain consideration commensurate with his services and as contemplated hereby; and
WHEREAS , the Company and Balthrop desire to resolve any and all differences that could exist between them prior to entering into an arrangement whereby Balthrop provides consulting services for the Company.
NOW, THEREFORE , in consideration of the promises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt, adequacy and sufficiency of which are hereby acknowledged by each party hereto, the parties hereby agree as follows:
1. Engagement; Term . As consideration for, and conditioned upon, the agreement by Balthrop and the Company to release any and all claims against each other, as more fully set forth below, the Company hereby agrees to engage Balthrop as a consultant beginning on the date hereof (the “Engagement Date”) and Balthrop agrees to provide the services described herein. This Agreement will automatically terminate six (6) months after the Engagement Date (the “Term”).

2. Services of Balthrop . Balthrop agrees to advise the Company’s Chief Executive Officer and the Board of Directors of the Company on strategic matters and other transitional and consulting services to be reasonably requested and authorized by the Company’s Chief Executive Officer from time to time during normal work hours. Balthrop accepts such engagement and represents and warrants to the Company that he will provide the services and perform his duties and responsibilities hereunder in a timely, competent and professional manner, consistent with this Agreement and all applicable laws and regulations.

3. Payments and Benefits . Provided that Balthrop has executed and delivered to the Company on or prior to the date hereof, and has not revoked during the seven (7) day revocation period following the date hereof (the “Revocation Period”), the general release referred to in Section 7 of this Agreement and attached hereto as Exhibit A (the “Release”), the Company shall make the payments and provide the benefits set forth in this Section 3.

3.1    For the services rendered hereunder by Balthrop, the Company will pay to Balthrop $58,333 per month, with such payments commencing on the first regularly scheduled accounting period which occurs after the expiration of the Revocation Period.
  
3.2    Throughout the course of his employment, Balthrop has received the awards under various Company equity plans which remain unvested as of the Engagement Date as set forth on Exhibit B (collectively, the “Equity Awards”). Balthrop and the Company agree that such Equity Awards shall continue to vest in accordance with the terms of the applicable plans during the Term so long as Balthrop continues to provide the services described in Section 2 on the same schedule as they vested during the period of Balthrop’s employment with the Company. The portion of the Equity Awards that remain unvested as of the end of the Term shall terminate in accordance with the terms of the applicable plans. In addition, notwithstanding the terms of the applicable Company equity plans and equity award agreements, all options to purchase common stock of the Company held by Balthrop as of the date hereof and that are either exercisable as of the date hereof or become exercisable during the Term pursuant to this Section 3.2 shall remain exercisable until October 14, 2016, at which time such options shall terminate immediately and become void and of no effect.





3.3    As contemplated by that certain Employment Agreement dated as of May 15, 2004, between Balthrop and the Company, as amended (the “Employment Agreement”), Balthrop will be paid any bonus earned under the Company’s Management Incentive Plan (the “MIP”) for the 2014 calendar year, in accordance with the terms of, and at the time specified in, the MIP and the Employment Agreement, prorating, for purposes of service under the MIP, Balthrop’s employment through the Engagement Date. Balthrop’s services as a consultant during the Term pursuant to Section 2 of this Agreement shall not count in the determination of any employment or service requirement for an award under the MIP.

3.4    Balthrop must receive prior written approval from the Company for, or the Company must later ratify in its reasonable discretion, any out-of-pocket expenses arising from services provided in accordance with this Agreement for which he seeks reimbursement, which will be reimbursed pursuant to the Company’s standard policies. All such expenses must be submitted in accordance with the Company’s Expense Policy.

4.     Relationship of Parties . In performing his obligations and services under this Agreement, Balthrop will be an independent contractor and will not represent himself as an agent of the Company. Nothing in this Agreement will be construed to constitute either party as the agent, employee or joint venturer of the other, nor will either party have the right to bind the other party or make any promises or representations on behalf of the other party. Balthrop will be solely responsible for the withholding and payment of social security and other applicable taxes, fees, and/or withholding on payments made to him by the Company as described herein and he will not be eligible for, and will have no claim against the Company for, fringe benefits, vacation pay, sick leave, retirement benefits, social security, worker’s compensation, disability or unemployment insurance benefits or other employee benefits of any kind.
5.     Confidential and Proprietary Information . Balthrop understands and acknowledges (i) that Section 5.6 of the Employment Agreement is incorporated herein in its entirety by this reference, mutatis mutandis , (ii) that Balthrop remains bound by the restrictions set forth therein during the Term and thereafter as set forth therein and (iii) that all Confidential Information (as defined in the Employment Agreement) he receives during the Term will be governed by Section 5.6 of the Employment Agreement.
6.     Termination of Engagement. Balthrop may terminate this Agreement before the expiration of the Term by giving the Company thirty (30) days’ written notice of intent to terminate the Agreement. In the event Balthrop chooses to terminate this Agreement for any reason other than as a result of any material breach of Company’s obligations hereunder, which is not cured within fifteen (15) days following written notice to Company by Balthrop, the Company will have no further obligation to Balthrop under this Agreement other than the prorated portion of the monthly fee through the last day Balthrop was retained by the Company. If the Company materially breaches any of its material obligations hereunder and such breach is not cured within fifteen (15) calendar days following written notice to Company by Balthrop, Balthrop may terminate this Agreement and shall be entitled to receive payment of the monthly fee by Company through the end of the Term in accordance with the normal payment schedule described in Section 3 of this Agreement and to all other rights Balthrop may have under this Agreement.
The Company may only terminate this Agreement for “cause,” or upon Balthrop’s death or a disability which prevents him from performing the consulting services described herein, which termination will be effective immediately. If the Company chooses to terminate this Agreement for “cause,” the Company will have no further obligation to Balthrop under this Agreement other than the prorated portion of the monthly fee through the last day Balthrop was retained by the Company. If the Company terminates this Agreement without cause (and Balthrop has not died or suffered a disability), Company shall pay Balthrop the monthly fee through the end of the Term in accordance with the normal payment schedule described in Section 3 of this Agreement.
For purposes of this Agreement, “cause” will include the following: (1) material failure or neglect by Balthrop to perform the services hereunder or other material breach of this Agreement; provided that such neglect, failure or breach remains uncured for a period of thirty (30) days after written notice describing the same is given to the Balthrop; (2) misappropriation of funds or property of the Company, securing or attempting to secure personally any profit in connection with any transaction entered into on behalf of the Company, material misrepresentation to the Company, or any violation of law or regulations on Company premises or to which the Company is subject; or (3) commission by Balthrop of an act involving moral turpitude, dishonesty, theft, or unethical business conduct, or conduct that materially impairs or injures the reputation of, or harms, the Company.
Upon any termination of this Agreement by the Company or Balthrop, for any reason, any Equity Awards which remain unvested as of the date of such termination shall cease to vest as of the date of such termination and terminate in accordance with the terms of the applicable plans. A termination of this Agreement by the Company or Balthrop, for any reason, will not




impact the Company’s obligation to pay Balthrop for any bonus earned under the MIP for the 2014 calendar year, in accordance with the terms of, and at the time specified in, the MIP and the Employment Agreement.
7.     Release . On the date hereof, Balthrop and the Company will execute and deliver the Release attached hereto as Exhibit A .
8.     Miscellaneous .
8.1     Amendments . This Agreement may not be amended, supplemented, canceled or discharged, except by written instrument executed by the party against whom enforcement is sought.
8.2     Notices . Any notice necessary under this Agreement must be addressed as set forth below:
To the Company:    
        
Luminex Corporation.
12212 Technology Blvd.
Austin, Texas 78727
Fax: (512) 219-5195
Attn: General Counsel and Corporate Secretary
    
To Balthrop:

Mr. Patrick J. Balthrop, Sr.
133 Avenue B
Apalachicola, Florida 32320

Notices may also be addressed to either party at such other address as either party may hereafter designate in writing to the other. Any notice will be deemed effective upon receipt thereof by the addressee or two days after such notice has been mailed, return receipt requested, or sent by a nationally recognized overnight courier service, whichever comes first.
8.3.     Binding Effect; Assignment . The rights and obligations of this Agreement will bind and inure to the benefit of any successor of the Company by reorganization, merger or consolidation, or any assignee of all or substantially all of the Company's business and properties. The Company may assign its rights and obligations under this Agreement to any of its subsidiaries or affiliates without the consent of Balthrop. The Company will require any such purchaser, successor or assignee to expressly assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such purchase, succession or assignment had taken place. Balthrop’s rights or obligations under this Agreement may not be assigned by Balthrop.
8.4.     Applicable Law . This Agreement will be construed and enforced according to the laws of the State of Delaware.
8.5     Arbitration . All disputes with respect to interpretation of the provisions of this Agreement shall be resolved by binding arbitration in Austin, Texas, pursuant to the American Arbitration Association Employment Rules governing employer-promulgated plans then pertaining. Those arbitration rules of procedures shall be modified by this Section 8.5. No one shall serve as arbitrator who is in any way financially interested in this Agreement or in the affairs of any party hereto. The arbitrator will apply the substantive law of the State of Delaware and the United States. The parties shall pay expenses of arbitration pursuant to the American Arbitration Association Employment Rules governing employer-promulgated plans. If any position by either party hereunder, or any defense or objection thereto, is deemed by the arbitrator to have been unreasonable, the arbitrator shall assess, as part of the award against the unreasonable party or reduce the award to the unreasonable party, all or part of the arbitration expenses (including reasonable attorneys’ fees) of the other party and of the arbitrator.
8.6.     No Presumption Created . The parties acknowledge that they have independently negotiated the provisions of this Agreement, that they have had the opportunity to rely upon their own counsel as to matters of law and application, and that neither party has relied on the other party with regard to such matters. The parties expressly agree that there will be no presumption created as a result of either party having prepared in whole or in part any provision of this Agreement.




8.7.     Counterparts . This Agreement may be executed in any number of counterparts, each of which will be deemed to be an original instrument, but all of which taken together will constitute but one instrument.
8.8.     Headings . The headings of the various sections and articles of this Agreement are inserted merely for convenience and do not expressly or by implication limit, define or extend the specific terms of the section or article so designated.
8.9.     Severability . The parties have carefully reviewed the provisions of this Agreement and agree that they are fair and equitable. However, in light of the possibility of differing interpretations of law and changes in circumstances, the parties agree that if any one or more of the provisions of this Agreement are determined by a court of competent jurisdiction to be invalid, void or unenforceable, the remainder of the provisions of this Agreement will, to the extent permitted by law, remain in full force and effect and will in no way be affected, impaired or invalidated.
8.10.     Additional Covenants .
In additional consideration of the Company’s entering into this Agreement and its agreement to provide him with Trade Secret and Proprietary Information necessary for him to provide the services hereunder, Balthrop agrees as follows:
8.10.1    Balthrop agrees to immediately disclose any potential or actual activity, including business activities and/or other employment, where his role or interest is in direct conflict with the Company’s interest. Although such activities are not automatically prohibited, written approval from the Company’s general counsel (such approval not to be unreasonably withheld or delayed) is required to participate in any such activity. Balthrop’s obligation to provide written disclosure of potential conflicts of interest, or the appearance of conflicts of interest, and to have such activities reviewed and approved in advance by the Company’s general counsel, continues throughout the Term.
8.10.2    During the Term and for a period of one (1) year subsequent to the conclusion of the Term, Balthrop agrees that he will not, without the prior express written permission of the Company’s general counsel, work as an employee, officer, consultant, contractor, advisor, or agent of any company that is a customer, supplier, or competitor of the Company or its related entities and be directly involved in activities that are directly in competition with the Company. During the Term and for a period of one (1) year subsequent to the conclusion of the Term, Balthrop agrees not to solicit the business of any current or prospective customer of the Company and which the Company has notified Balthrop, or Balthrop is actually aware, is a prospective customer of the Company for any company that competes with the Company.
8.10.3    During the Term and for a period of one (1) year subsequent to the conclusion of the Term, Balthrop will not solicit, induce, or attempt to induce, any employee of the Company or any subsidiary, or any individual who has been employed by the Company or any subsidiary in the prior six months, (i) to terminate his or her employment with the Company or any subsidiary or (ii) to work for any person, firm, partnership, corporation, or other entity which provides services materially similar to or competitive with the business of the Company or any subsidiary.
8.10.4    Balthrop agrees to comply with all Company policies applicable to consultants and applicable laws during the Term.
8.11     Section 409A . It is the intent of the parties that all of the payments and benefits under this Agreement either be exempt from or comply with Section 409A of the Internal Revenue Code of 1986, as amended, and applicable guidance thereunder, and this Agreement shall be so interpreted.  It is intended that that the payments under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Section 409A of the Code, including those provided under Treasury Regulations 1.409A-1(b)(4) (regarding short-term deferrals), 1.409A-1(b)(9)(iii) (regarding the two-times, two (2) year exception) and 1.409A-1(b)(9)(v) (regarding reimbursements and other separation pay). Notwithstanding anything to the contrary herein, if Balthrop is deemed to be a “specified employee” (as such term is defined under Treasury Regulation 1.409A-1(i)(1)) of Company, as determined in accordance with the Company’s “specified employee” determination procedures, and (ii) any payments to be provided to Balthrop pursuant to this Agreement constitute “deferred compensation” for purposes of Section 409A of the Code and are or may become subject to the additional tax under Section 409A(a)(1)(B) of the Code or any other taxes or penalties imposed under Section 409A of the Code if provided at the time otherwise required under this Agreement, then such payments shall be delayed until the date that is six (6) months after the date of Balthrop’s “separation from service” (as such term is defined under Treasury Regulation 1.409A-1(h)) or, if sooner, the date of Balthrop’s death. Any payments delayed pursuant to this Section 8.11 shall be made in a lump sum on the first day of the seventh month following Balthrop’s “separation from service” (as such term is defined under Treasury Regulation 1.409A-1(h)) or, if sooner, the date of Balthrop’s death and any remaining payments shall be paid according to the schedule otherwise applicable to the payments. To the extent that any




expenses are reimbursed under this Agreement, then such amount shall be reimbursed in accordance with Section 1.409A-3(i)(1)(iv) of the Treasury regulations, including (i) the amount eligible for reimbursement in one calendar year may not affect the amount eligible for reimbursement in any other calendar year, (ii) any reimbursement must be made on or before the last day of the calendar year following the calendar year in which the expense was incurred, and (iii) the right to any reimbursement is not subject to liquidation or exchange for another benefit.

[ Remainder of page intentionally left blank. Signature page follows. ]






IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.
 
 
 
 
LUMINEX CORPORATION
 
 
 
 
By:
/s/ David S. Reiter
 
Name:
David S. Reiter
 
Its:
General Counsel and Senior Vice President
 
 
 
 
 
 
 
 
 
ACCEPTED AND AGREED TO:
 
 
 
 
 
 
 
 
/s/ Patrick J. Balthrop, Sr.
 
 
Patrick J. Balthrop, Sr.
 
 




Signature Page to Consulting Agreement by and between Luminex Corporation and Patrick J. Balthrop, Sr.



Exhibit A


GENERAL RELEASE AGREEMENT


THIS GENERAL RELEASE AGREEMENT (this “Agreement”) dated as of this 14 th day of October, 2014 (the “Effective Date”), is by and between Patrick J. Balthrop, Sr. (“Executive”) and Luminex Corporation (“Luminex”).

WHEREAS, Executive’s employment with Luminex has terminated pursuant to that certain Employment Agreement dated as of May 15, 2004, as amended (the “Employment Agreement”);

WHEREAS, Executive and Luminex are parties to a Consulting Agreement of even date herewith (the “Consulting Agreement”);

WHEREAS, as a condition to the agreement by Luminex to enter into the Consulting Agreement and the receipt of certain payments and benefits following the date of this Agreement under the Consulting Agreement and in consideration for the execution and delivery of this Agreement by Luminex, Executive has agreed to execute and deliver this Agreement; and

WHEREAS, in consideration for the agreements and covenants of the Executive contained in the Consulting Agreement and the execution and delivery of this Agreement by the Executive, Luminex has agreed to execute and deliver this Agreement.

NOW, THEREFORE, in consideration of the foregoing premises and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

1.     Termination of Employment . Executive and Luminex hereby agree that Executive’s employment with Luminex has terminated pursuant to Section 2.2.3 of the Employment Agreement effective as of the Effective Date. To the extent he continues to hold any such positions or directorships, Executive hereby resigns all positions and directorships he holds with Luminex and any and all of Luminex’s subsidiaries and affiliates.

2.     Release by Executive . Executive, on his own behalf and on behalf of the Executive Released Parties (defined below), hereby irrevocably and unconditionally releases and forever discharges Luminex, its subsidiaries and other affiliates and their respective agents, employees, representatives, officers, directors, stockholders, trustees and attorneys, past and present, and the heirs, successors and assigns of all of the foregoing (collectively, the “Released Parties”) from any and all debts, liabilities, claims, demands, actions or causes of action, suits, judgments or controversies of any kind whatsoever (except as set forth below) arising from Executive’s relationship (including without limitation as a stockholder) to, employment with or service as an employee, officer, director, or manager of Luminex or its subsidiaries and affiliates, and the termination of any or all of the foregoing relationships (collectively, the “Claims”) against the Released Parties, that now exist or that may arise in the future out of any matter, transaction or event occurring prior to or on the Effective Date, including without limitation, any claims of breach of contract or for severance or other termination pay (except as set forth in Section 4 below), or claims of unlawful retaliation, harassment or discrimination or the denial of some benefit or protection provided to employees (for example, discrimination on the basis of age, sex, race, handicap, disability, religion, color or national origin or for complaining of such) under any federal, state or local law, rule or regulation, including, but not limited to, the Age Discrimination in Employment Act of 1967, 29 U.S.C. Section 621, et seq. , Title VII of the Civil Rights Act of 1964, as amended, the Employee Retirement Income Security Act (ERISA), the Worker Adjustment and Retraining Notification Act of 1988 (WARN), the National Labor Relations Act (NLRA), and/or the Fair Labor Standards Act (FLSA), the Americans with Disabilities Act (ADA), the Genetic Information Nondiscrimination Act (GINA), and/or the Family and Medical Leave Act (FMLA). Except as set forth below, Executive further agrees not to file or bring any claim, suit, civil action, complaint, arbitration or administrative action (any of the foregoing, an “Action”) in any city, state or federal court or agency or arbitration tribunal with respect to any Claim against any of the Released Parties or (except as may be required by law) assist any other person or entity with any Action against any of the Released Parties. Notwithstanding anything to the contrary contained in this Agreement, Executive does not release any of the Released Parties and shall not be prohibited from filing or bringing an Action with respect to any right Executive otherwise may have now or in the future (i) to receive distributions or dividends made in respect of Luminex’s capital stock or (ii) to be indemnified by Luminex under the Certificate of Incorporation or Bylaws of Luminex (as the same are currently in effect), any resolution adopted by the Board of Directors of Luminex, or any other separate written agreement or instrument requiring Luminex to indemnify Executive or (iii) to receive workers’ compensation claims or (iv) to receive Accrued Obligations (as such term is defined in the Employment Agreement) or (v) to stock, options, and other equity-based compensation that vested prior to the Effective Date or that vests subsequent to the Effective Date pursuant to the Employment Agreement, the Consulting




Agreement or an applicable Luminex long-term incentive plan (which stock, options or other equity-based compensation shall be governed by the terms and provisions of the applicable written agreement(s) or instrument(s) and/or the applicable Luminex incentive plan) or (vi) to vested benefits payable under retirement and other employee benefit plans covering Executive (which benefits shall be governed by the terms and provisions of the applicable plan) or (vii) pursuant to the Consulting Agreement.

3.     Release by Luminex . Luminex, on its own behalf and on behalf of the Released Parties, hereby irrevocably and unconditionally releases and forever discharges Executive and his heirs, successors and assigns (collectively, the “Executive Released Parties”) from any and all debts, liabilities, claims, demands, actions or causes of action, suits, judgments or controversies of any kind whatsoever (except as set forth below) arising from Executive’s employment with or service as an employee, officer, director, or manager of Luminex or its subsidiaries and affiliates, and the termination of any or all of the foregoing relationships against the Executive Released Parties, that now exist. Except as set forth below, Luminex further agrees not to file or bring any Action in any city, state or federal court or agency or arbitration tribunal with respect to any Claim against any of the Executive Released Parties or (except as may be required by law) assist any other person or entity with any Action against any of the Executive Released Parties. Notwithstanding anything to the contrary contained in this Agreement, Luminex does not release any of the Executive Released Parties and shall not be prohibited from filing or bringing an Action with respect to (i) a breach by Executive after the Effective Date of any of Executive’s obligations under the Employment Agreement that by their terms survive termination of the Employment Agreement, including without limitation the provisions of Article 5 of the Employment Agreement, or (ii) in connection with any claim for indemnification by Executive, any obligation or burden of proof applicable to Executive that is a condition to Executive’s right to be indemnified by Luminex under the Certificate of Incorporation or Bylaws of Luminex (as the same are currently in effect), any resolution adopted by the Board of Directors of Luminex, or any other separate written agreement or instrument requiring Luminex to indemnify Executive or (iii) any Claims that arise out of any criminal or fraudulent activity, willful misconduct or gross negligence of Executive or (iv) any of Executive’s obligations under the Consulting Agreement.

4.     Accrued Obligations and Benefits . Executive shall be entitled to receive from Luminex the Accrued Obligations under Section 2.2.3 in the Employment Agreement. In addition, Executive acknowledges that the payments and benefits offered in connection with the Consulting Agreement are in exchange in part for Executive’s execution of this Agreement. Executive acknowledges that no other promise or agreements of any kind have been made to Executive or with Executive by any person or entity whatsoever to cause Executive to sign this Agreement. Executive further acknowledges and agrees that the Accrued Obligations, together with any other payments or benefits that may be due under the terms of the Employment Agreement and the Consulting Agreement, shall constitute full accord and satisfaction of all obligations, including without limitation any and all severance obligations, in connection with Executive’s employment.

5.     Disclaimer of Liability . Executive acknowledges that this Agreement shall not in any way be construed as an admission by Executive or any of the Released Parties of any wrongful or illegal act against the other or any other person, and that Executive and the Released Parties expressly disclaim any liability of any nature whatsoever arising from or related to the subject of this Agreement.

6.     COMPETENCY . EXECUTIVE ACKNOWLEDGES THE FOLLOWING:

(a)
THAT HE FULLY COMPREHENDS AND UNDERSTANDS ALL OF THE TERMS OF THIS AGREEMENT AND THEIR LEGAL EFFECTS;

(b)
THAT HE IS COMPETENT TO EXECUTE THIS AGREEMENT;

(c)
THAT IT IS EXECUTED KNOWINGLY AND VOLUNTARILY AND WITHOUT RELIANCE UPON ANY STATEMENT OR REPRESENTATION OF ANY RELEASED PARTY OR ITS REPRESENTATIVES;

(d)
THAT HE HAS BEEN ADVISED IN WRITING TO CONSULT WITH AN ATTORNEY BEFORE EXECUTING THIS AGREEMENT AND THAT HE HAS HAD THE OPPORTUNITY TO CONSULT WITH AN ATTORNEY OF HIS CHOICE REGARDING THIS AGREEMENT;

(e)
THAT EXECUTIVE DOES NOT WAIVE RIGHTS OR CLAIMS THAT MAY ARISE AFTER THE DATE THIS AGREEMENT IS EXECUTED;





(f)
THAT EXECUTIVE WAIVES RIGHTS OR CLAIMS UNDER THIS AGREEMENT ONLY IN EXCHANGE FOR CONSIDERATION IN ADDITION TO ANYTHING OF VALUE TO WHICH THE EXECUTIVE WAS ALREADY ENTITLED;

(g)
THAT CERTAIN BENEFITS CALLED FOR IN THE CONSULTING AGREEMENT TO BE PAID FOLLOWING THE DATE OF THIS AGREEMENT WOULD NOT BE PROVIDED TO ANY EXECUTIVE TERMINATING HIS OR HER EMPLOYMENT WITH LUMINEX WHO DID NOT SIGN A RELEASE SIMILAR TO THIS AGREEMENT, THAT SUCH BENEFITS WOULD NOT HAVE BEEN PROVIDED IN THEIR ENTIRETY HAD THE EXECUTIVE NOT SIGNED THIS AGREEMENT, AND THAT SUCH BENEFITS ARE IN EXCHANGE IN PART FOR THE SIGNING OF THIS AGREEMENT;

(h)
THAT HE HAS HAD A PERIOD OF AT LEAST 21 DAYS WITHIN WHICH TO CONSIDER THIS AGREEMENT;

(i)
THAT FOR A PERIOD OF SEVEN DAYS FOLLOWING THE EXECUTION OF THIS AGREEMENT, EXECUTIVE MAY REVOKE AGREEMENT AND IT SHALL NOT BECOME EFFECTIVE OR ENFORCEABLE UNTIL THE SEVEN-DAY PERIOD HAS EXPIRED OR SUCH LATER DATE AS PROVIDED FOR HEREIN.

7.     Parties in Interest . This Agreement is for the benefit of the Released Parties and shall be binding upon Executive and his representatives and heirs.

8.     Governing Law . This Agreement and the rights and obligations of Executive hereunder shall be governed by and construed and enforced in accordance with the substantive laws of the State of Texas.

9.     Amendment . This Agreement may not be clarified, modified, changed or amended except in writing and signed by Executive and Luminex or a successor-in-interest of Luminex.

10.     Non-disparagement . Executive agrees that he will refrain from speaking ill of or making any disparaging comment about Luminex or any of Luminex’s then-current management, other employees or contractors, following the termination of his employment except as may be necessary or advisable, in the reasonable judgment of Executive, to enforce his rights under this Agreement or the Consulting Agreement, enforce claims arising after the Effective Date and not released in this Agreement, or defend a legal action brought against Executive by any of the Released Parties. Notwithstanding anything to the contrary herein, it shall not be a violation of this Section 10 for Executive to provide truthful information or a good faith assessment of the qualifications of a Luminex employee or contractor if asked by a person with a reasonable professional or civic reason for such inquiry. Luminex agrees that it will refrain from speaking ill of or making any disparaging comment about Executive following the termination of his employment except as may be necessary or advisable, in the reasonable judgment of Luminex, to (i) to enforce its rights under the Employment Agreement, the Consulting Agreement or this Agreement not released in this Agreement or (ii) defend a legal action brought against any of the Released Parties by Executive or (iii) comply with applicable securities laws or protect Luminex from potential liability.

11.     Enforcement of Laws . Nothing in this Agreement affects the rights and responsibilities of the Equal Employment Opportunity Commission (the “Commission”) to enforce the anti-discrimination laws, and this waiver does not affect Executive’s right to file a charge or participate in an investigation or proceeding with the Commission. However, Executive waives any rights or claims, known or unknown, to participate in any recovery under any proceeding or investigation by the Commission or any state or local commission concerned with the enforcement of anti-discrimination laws. In accordance with 29 C.F.R. § 1625.23(b), nothing within this Agreement is intended to preclude Executive from bringing a lawsuit to challenge the validity of the release language contained in this Agreement with respect to a claim under the Age Discrimination in Employment Act.

12.     Severability . If any provision of this Agreement is held to be illegal, invalid or unenforceable under present or future laws, such provision shall be fully severable and this Agreement shall be construed and enforced as if such illegal, invalid or unenforceable provision never comprised a part hereof; and the remaining provisions hereof shall remain in full force and effect and shall not be affected by the illegal, invalid or unenforceable provision, and there shall be added automatically as part of this Agreement a provision as similar in its terms to such illegal, invalid or unenforceable provision as may be possible and be legal, valid and enforceable.





13.     Entire Agreement .    The Consulting Agreement, the Employment Agreement and this Agreement constitute the entire agreement and understanding between the parties. The Executive has not relied on any oral statements that are not expressly stated in the Consulting Agreement, the Employment Agreement or this Agreement.

[ Remainder of page intentionally left blank. Signature page follows. ]






IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.
 
 
 
 
LUMINEX CORPORATION
 
 
 
 
By:
/s/ David S. Reiter
 
Name:
David S. Reiter
 
Its:
General Counsel and Senior Vice President
 
 
 
 
 
 
 
 
 
 
 
/s/ Patrick J. Balthrop, Sr.
 
 
Patrick J. Balthrop, Sr.




Signature Page to General Release Agreement by and between Luminex Corporation and Patrick J. Balthrop, Sr.



Exhibit B

Equity Awards

Option Awards
 
Stock Awards
Unvested Options (#)
 
Option Exercise Price ($)
 
Option Grant Date
 
 
Award Grant Date
 
Unvested Restricted Stock Awards (#)
11,783
 
22.71
 
03/13/2012
 
 
 
23,892
 
17.24
 
03/08/2013
 
 
 
 
 
 
 
03/11/2010
 
6,768
 
 
 
 
03/11/2011
 
6,134
 
 
 
 
03/13/2012
 
20,608
 
 
 
 
03/08/2013
 
27,146
 
 
 
 
03/12/2014
 
86,395




Exhibit 10.2


EMPLOYMENT AGREEMENT

 
THIS EMPLOYMENT AGREEMENT (this “ Agreement ”) is made and entered into to be effective as of 5:00 pm (CDT) on October 14, 2014 (the “ Effective Date ”) by and between Luminex Corporation, a Delaware corporation ("Luminex”) and Nachum Shamir (“ Executive ”).

RECITAL

WHEREAS, Executive is to be employed as the President and Chief Executive Officer of Luminex;

WHEREAS, Luminex and Executive wish to document the terms of the employment of Executive in such capacity; and

WHEREAS, Executive has represented to Luminex and Luminex has relied on Executive’s representation that the execution of this Agreement by Executive, and the provision of services by Executive to Luminex as contemplated in this Agreement, will not conflict with, or cause Executive or any other person or entity to be in breach of, (i) any other contract to which Executive is a party or (ii) any duty which Executive may owe to any other person or entity.

AGREEMENT

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

1. Duties; Disclosure of Information .

1.1     Duties . During the term of this Agreement (including all renewal periods, if any, the “ Term ”), Executive agrees to be employed by and to serve Luminex as President and Chief Executive Officer, and Luminex agrees to employ and retain Executive in such capacities subject to the provisions of this Agreement. Executive shall have such duties and responsibilities as are customarily assigned to individuals serving in such positions, as the same may be described in Luminex’s bylaws, and such other duties consistent with Executive’s titles and positions as the Board of Directors of Luminex (the “ Board ”) shall from time to time lawfully direct. Luminex shall offer to Executive a position on the Board within a reasonable amount of time after the execution of this Agreement. Executive shall devote all of his business time, energy, and skill to the business of Luminex; provided, however, that he shall be exempt from doing so during vacation time as set forth in Paragraph 3.4.1 , absence for sickness or similar disability, and time spent performing services for any charitable, religious or community organizations, so long as such services do not materially interfere with the performance of Executive’s duties hereunder. It is understood and agreed that Executive is a member of the Board of Directors of Invendo Medical GmbH, a privately-held German company, and currently owns approximately 1.6% of the equity of Rosetta Genomics Ltd., a company of the State of Israel, which is publicly listed on NASDAQ under the symbol ROSG. Luminex consents to Executive continuing to be a member of the Board of Directors of Invendo Medical GmbH and remaining a stockholder of Rosetta Genomics Ltd. without being in breach of this Agreement, so long as (a) Executive’s duties to Luminex take priority and (b) the provisions of Paragraph 5 remain in full force and effect as to such companies and activities. Prior to Executive’s acceptance of an invitation to sit on any other for-profit Board of Directors, he shall seek the advance approval of the Board, which the Board may withhold or grant in its sole discretion. Upon sixty (60) days prior written notice from the Board of its request that Executive resign from any such other third party, for-profit company’s Board of Directors, Executive shall so tender his resignation to such other third party company Board of Directors. Executive shall at all times act in a manner consistent with, and otherwise comply with, any and all codes of business conduct and ethics of Luminex and all insider trading policies of Luminex, as the same may be adopted or amended from time to time.

1.2     Disclosure of Competitively Sensitive Information . During the Term, Luminex shall disclose to Executive various confidential and competitively sensitive information, including without limitation pricing and marketing information and strategies being used and contemplated to be used by Luminex and human resources information.





2. Term and Termination .

2.1     Term . Subject to Paragraph 2.2 , the term of employment of Executive by Luminex shall be two (2) years commencing on the Effective Date and shall thereafter automatically renew for successive additional one-year terms unless either party provides the other with written notice of its intent not to renew this Agreement at least ninety (90) days prior to the end of the Term (including any renewal term, as applicable) unless terminated earlier pursuant to the provisions of this Agreement.

2.1     Termination of Employment .

2.2.1     Termination For Cause . “ Termination For Cause ” shall mean the termination by Luminex of Executive’s employment with Luminex as the result of conduct that the Board has determined, in good faith, constitutes (i) the failure of Executive to substantially perform his duties hereunder; (ii) Executive’s engaging in misconduct that has caused or is reasonably expected to result in material injury to Luminex or any of its affiliates; (iii) Executive’s violation of any material Luminex policy; (iv) Executive’s indictment or conviction of, or entering a plea of guilty or nolo contendere to, a crime that constitutes a felony, or a misdemeanor involving moral turpitude; or (v) the material breach by Executive of any of his obligations hereunder or under any other written agreement or covenant with Luminex or any of its affiliates, in each case with respect to sections (i), (ii), (iii) and (v) above after the receipt of written notice from Luminex specifying the grounds for Termination For Cause and failure by Executive to cure such breach within thirty (30) days from receipt of such notice, to the extent such breach can be cured. Executive’s inability to perform his obligations under this Agreement despite his best efforts as a result of a permanent or temporary disability (as evidenced by a written determination from a physician chosen by Executive and reasonably acceptable to Luminex) shall not result in a Termination For Cause. Upon receipt of the written notice from Luminex specifying the grounds for Termination For Cause, Executive shall be provided an opportunity to be heard by the Board within the first ten (10) business days of the thirty (30) day cure period, and if that is not feasible, then the thirty (30) day cure period will be extended on a day-for-day basis thereafter until Executive is provided such opportunity to be heard by the Board. In this context, “heard by the Board” shall be a hearing at a duly noticed and convened special meeting of the Board in compliance with the bylaws of Luminex. In the event that the Board does not rescind its written notice or Executive fails to cure the breach (excluding section (iv) above) to the reasonable satisfaction of the Board within the thirty (30) day cure period, as provided above, the termination shall be effective as of the date that Luminex notifies Executive, in writing, of his termination following the expiration of the thirty (30) day cure period (as the same may be extended as provided above). Upon any Termination For Cause, Executive shall be paid the Accrued Obligations (defined below) within three (3) business days following the effective date of termination and no more. In recognition of the extreme reputational damage to Executive of a Termination For Cause, prior to Luminex providing Executive with the written notice of termination as provided above, Luminex shall provide a five (5) day opportunity for Executive to submit his written resignation as an Actual Voluntary Termination.

2.2.2     Termination Other Than For Cause . “ Termination Other Than For Cause ” shall mean (i) termination by Luminex of Executive’s employment with Luminex for any reason other than Termination For Cause, Termination by Reason of Death, Termination by Reason of Incapacity or Termination Upon Expiration of Agreement or (ii) termination by Executive upon constructive termination (“ Constructive Termination ”) of Executive’s employment with Luminex by reason of (A) a material reduction in Executive’s Base Salary (defined below), unless such reduction is a part of an across-the-board percentage decrease in base salaries affecting all executive officers of Luminex equally as to the percentage; provided, that, in any event, Luminex shall not reduce Executive’s Base Salary below the greater of 90% of Executive’s Base Salary as in effect on the Effective Date, or 90% of Executive’s Base Salary in effect immediately prior to such reduction; (B) a reduction in Executive’s title from President and Chief Executive Officer of Luminex (whether by reason of Executive’s removal from any of such offices or Luminex’s failure to reappoint Executive to any of such offices); (C) a Material Diminution (defined below); (D) a requirement that Executive change his principal place of business to a location that is outside the Office Area (defined below), or (E) Luminex’s material breach of this Agreement (each, a “ Constructive Termination Event ”). In order to constitute Constructive Termination, Executive must notify Luminex, in writing, of the Constructive Termination Event within sixty (60) days of its occurrence (the “ Constructive Termination Notice Period ”) and Luminex must fail to cure the Constructive Termination Event, to the extent such event can be cured, within thirty (30) days of its receipt of such notice (the “ Constructive Termination Cure Period ”). Termination Other Than For Cause may be effected by Luminex at any time by providing Executive with written notice of such termination. The termination shall be effective as of the date of the notice or such later date as may be determined by Luminex. Executive may also effect a Termination Other Than For Cause upon written notice to Luminex prior to the expiration of the Constructive Termination Notice Period following the occurrence of a Constructive Termination Event; provided that (i) failure by Executive to deliver written notice of the occurrence of a Constructive Termination Event within the Constructive Termination Notice Period and/or (ii) failure by Executive to terminate employment within ninety (90) days following Luminex’s failure to cure the Constructive Termination Event prior to expiration of the Constructive Termination Cure Period shall constitute Executive’s waiver of his right to terminate upon Constructive Termination of Executive’s employment with Luminex with respect to such Constructive Termination Event. Upon any Termination Other Than For Cause, Executive shall be paid (i) within




three (3) business days following the effective date of termination the amount of the Accrued Obligations; (ii) the Accrued Bonus, if any, at the same time at which other executives of Luminex receive their annual bonus in respect of the calendar year in which termination occurred; and (iii) the Severance Compensation provided in Paragraph 4.1 . For purposes of this Agreement, “ Material Diminution ” means a material diminution by Luminex of Executive’s duties, powers, authority, functions or responsibilities without Executive’s consent, such that Executive is left with such duties, powers, authority, functions and responsibilities (when viewed in the aggregate) that are materially diminished compared to both (i) those duties, powers, authority, functions and responsibilities conferred upon Executive at the Effective Date and (ii) those duties, powers, authority, functions and responsibilities that are most typically conferred upon the chief executive officer of companies having revenues comparable to Luminex (based on the revenues of Luminex at the time of determination). For purposes of this Agreement, “ Office Area ” means the geographical area within a fifty (50) mile radius of Luminex’s current principal office at 12212 Technology Blvd., Austin, Texas.

2.2.3     Actual Voluntary Termination . “ Actual Voluntary Termination ” shall mean termination by Executive of Executive’s employment with Luminex for any reason other than Termination For Cause, Termination Other Than For Cause, Termination by Reason of Death or Termination by Reason of Incapacity. In the event of an Actual Voluntary Termination, Executive shall be paid during the next normal pay cycle following the effective date of termination the amount of the Accrued Obligations and no more.

2.2.4     Termination by Reason of Incapacity . If, during the Term, Executive shall become Permanently Disabled (defined below), Luminex may terminate Executive's employment with Luminex effective on the earliest date permitted under applicable law, if any, and such termination shall be deemed “ Termination by Reason of Incapacity ”. Upon termination of employment under this Paragraph, Executive shall be paid (i) on the next normal pay cycle following the effective date of termination the amount of the Accrued Obligations; (ii) the Accrued Bonus, if any, at the same time at which other executives of Luminex receive their annual bonus in respect of the calendar year in which termination occurred; and (iii) the Severance Compensation provided in Paragraph 4.2 . As used herein, Executive shall be deemed “ Permanently Disabled ” if Executive is (i) collecting long-term disability payments under a long-term disability plan established for the benefit of Luminex's employees or executives generally or a reasonably similar plan so long as such plan utilizes a definition of “disability” provided for in Section 1.409A-3(i)(4) of the Treasury Regulations (“ Section 409A Definition of Disability ”) or (ii) if, and only if, no such long-term disability plan is in effect at the time of determination or such plan fails to utilize a Section 409A Definition of Disability, an independent physician selected by Luminex and reasonably acceptable to Executive makes a written determination that Executive is unable to engage in any substantial gainful activity, despite his best efforts, by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuing period of not less than twelve (12) months. The determination of any selected independent physician is final and binding on the parties and shall be made after taking into account such competent medical evidence as shall be presented to the independent physician by Executive and/or Luminex or by any physician or group of physicians or other competent medical experts employed by Executive and/or Luminex to advise such independent physician, and in accordance with Section 409A of the Internal Revenue Code of 1986, as amended (the “ Code ”).

2.2.5     Termination by Reason of Death . In the event of Executive’s death during the Term, Executive’s employment with Luminex shall be deemed to have terminated as of the date on which his death occurs and upon receipt of a certified death certificate, and the estate of Executive shall be paid (i) within fifteen (15) days following the effective date of termination the amount of the Accrued Obligations; (ii) the Accrued Bonus, if any, at the same time at which other executives of Luminex receive their annual bonus in respect of the calendar year in which termination occurred; and (iii) the Severance Compensation provided in Paragraph 4.3 .

2.2.6     Termination Upon Expiration of Agreement . In the event that Luminex refuses for any reason to extend this Agreement by giving written notice at least ninety (90) days prior to the initial or any renewal period as set forth in Paragraph 2.1 , Executive shall be paid upon his subsequent termination of employment (i) within three (3) business days following the effective date of termination the amount of the Accrued Obligations; (ii) the Accrued Bonus, if any, at the same time at which other executives of Luminex receive their annual bonus in respect of the calendar year in which termination occurred; and (iii) the Severance Compensation provided in Paragraph 4.4 . In the event that Executive refuses for any reason (except as otherwise provided herein) to extend this Agreement by giving written notice at least ninety (90) days prior to the initial or any renewal period as set forth in Paragraph 2.1 , the termination shall be deemed an Actual Voluntary Termination; provided, however, that this ninety (90) day period for Executive shall be reduced on a day-for-day basis while any Constructive Termination Event that Luminex has been given notice of prior to such ninety (90) day period remains unremedied by Luminex as provided above during such ninety (90) day period.





2.2.7     Termination of Relationship with Affiliated Entities . Unless agreed by Luminex (or a subsidiary thereof) and Executive in a separate written agreement (other than corporate minutes, resolutions, charter documents, bylaws and partnership agreements), upon the termination of Executive’s employment with Luminex for any reason, Executive shall tender a written resignation of any positions he may have with Luminex and any and all of Luminex’s direct and indirect subsidiaries.

2.2.8     Definition of Accrued Obligations and Accrued Bonus . As used in this Agreement, “ Accrued Obligations ” means all accrued but unpaid salary, accrued but unpaid vacation, and similar pay (all determined in accordance with Luminex’s policies then in effect), any appropriate unreimbursed business expenses incurred by Executive in connection with his duties hereunder and appropriately documented (Executive being afforded a reasonable opportunity to submit final expense reimbursement requests), and any vested and accrued benefits provided under employee benefit programs maintained by Luminex, including qualified and nonqualified programs which shall be payable according to their terms. If (i) termination takes place other than (a) for Cause or (b) as a result of Employee’s Actual Voluntary Termination, (ii) after March 31 of any calendar year, and (iii) as of the end of such calendar year during which termination occurred, all written performance criteria for Executive to have earned the bonus for the calendar year have been satisfied, then a portion of Executive’s bonus compensation that otherwise would have been payable pursuant to Paragraph 3.2 , (the “ Accrued Bonus ”), shall deemed to have accrued on a prorata basis in an amount equal to a fraction, the numerator of which is the number of completed weeks of service prior to termination during the year and the denominator of which is 52. In addition, if (i) Executive is terminated after the end of a calendar year, other than (a) for Cause or (b) as a result of Employee’s Actual Voluntary Termination; and (ii) Executive earned bonus compensation pursuant to Paragraph 3.2 in respect of the most recently completed calendar year, which bonus compensation has not been paid to Executive at the time of termination; then “ Accrued Bonus ” also shall include such full bonus earned in respect of the most recently completed calendar year.

3. Salary, Benefits, Bonus and Stock .

3.1     Base Salary . As payment for the services to be rendered by Executive as provided in Paragraph 1 and subject to the terms and conditions of Paragraph 2 , Luminex agrees to pay to Executive a “ Base Salary ” at the rate of $600,000 per annum. The Base Salary shall be paid in arrears in semi-monthly payments and according to the normal pay periods of Luminex. The Board, or the Compensation Committee thereof, shall review Executive’s Base Salary annually during the period of his employment hereunder and, in its sole discretion, may increase such Base Salary from time to time based upon Executive’s performance, the financial condition of Luminex, salaries of executives in similar positions at other comparable companies in the industry, and such other factors as the Board, or Compensation Committee thereof, shall consider relevant. The Base Salary shall be payable in accordance with the then-current payroll policies of Luminex.

3.2     Bonuses . Executive shall be eligible to receive a bonus each year in an amount up to the target bonus of 100% (or such higher percentage as may be determined from time to time by the Board or the Compensation Committee thereof) of Executive’s Base Salary during the Term and any extensions hereof, with the actual amount of any such bonus to be determined in the sole discretion of the Board. The Board is under no obligation to declare, and Luminex is under no obligation to pay, any bonus to Executive under the terms of this Agreement. In the event Executive and Luminex are parties to a written agreement or plan executed by both Luminex and Executive that governs bonus arrangements, and the provisions thereof conflict with this Paragraph 3.2 , the terms of such other written agreement or plan shall supersede this Paragraph 3.2 .

3.3     Change in Control . In the event that both (i) a Change in Control (defined below) of Luminex occurs during the Term and (ii) Executive's employment with Luminex (or, as applicable, its successor in interest) is terminated by Luminex for any reason at any time within six (6) months following the occurrence of the Change in Control of Luminex, in lieu of any Severance Compensation then owed or that otherwise would be owed in the future to Executive under Paragraph 4 of this Agreement, Luminex (or its successor in interest) shall pay Executive both the Accrued Obligations and a lump sum payment (the “ Change in Control Payment ”) in an aggregate amount equal to the sum of (i) the Bonus Amount (defined below), plus (ii) an amount equal to Executive's annual Base Salary (at the highest rate in effect during the period beginning six months immediately prior to the effective date of the Change in Control through the date of termination) within three (3) business days after the termination of Executive's employment. In addition, following the payment of the Change in Control Payment, Luminex shall also pay Executive the Accrued Bonus, if any, at the same time at which other executives of Luminex receive their annual bonus in respect of the calendar year in which termination occurred. In the interest of clarity, Luminex and Executive agree that, upon the termination of Executive's employment at any time within six (6) months following the occurrence of the Change in Control of Luminex, the provisions of Paragraphs 4.1 , 4.2 , 4.3 , 4.4 , and 4.6 shall automatically be deemed null and void and shall not apply with respect to any termination of Executive's employment (whether such termination is effected in connection with the Change in Control of Luminex or at any time within six (6) months following the Change in Control of Luminex), and under no circumstances shall Luminex ever be obligated to pay Executive both a Change in Control Payment and Severance




Compensation under Paragraph 4 . For purposes of this Agreement, a “ Change in Control ” of Luminex shall be deemed to have occurred if, after the date of this Agreement:

(A) any “ Person ” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”)) (other than an Approved Person (as defined below)) becomes the “ Beneficial Owner ” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of a majority of the then outstanding Common Stock of Luminex (“ Common Stock ”) (such Person, an “ Acquiring Person ”); or

(B) Luminex merges or consolidates with any other corporation or other entity, in each case other than a merger or consolidation which results in the voting securities of Luminex outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) at least a majority of the combined voting power of the voting securities of Luminex or such surviving entity outstanding immediately after such merger or consolidation; or

(C) Luminex sells or disposes of all or substantially all of Luminex's assets in one transaction or a series of related transactions; or

(D) If, as a result of nominations made by a person or group other than the Board of Directors of Luminex, individuals who prior to such nominations constitute the Directors of Luminex cease for any reason to constitute at least a majority thereof within the two year period following such nominations.

Notwithstanding the foregoing, to the extent that (i) any payment or vesting of an equity award under this Agreement is payable or becomes vested solely upon or following the occurrence of a Change in Control and (ii) such payment or vesting event is treated as “deferred compensation” for purposes of Section 409A of the Code, a Change in Control shall mean a “change in the ownership of Luminex,” a “change in the effective control of Luminex” or a “change in the ownership of a substantial portion of the assets of Luminex” as such terms are defined in Section 1.409A-3(i)(5) of the Treasury Regulations and in accordance with Section 1.409A-3(c) of the Treasury Regulations.

As used in this Agreement, “ Approved Person ” means (1) an employee benefit plan of Luminex (or a trustee or other fiduciary holding securities for such a plan), or (2) a corporation owned, directly or indirectly, by the stockholders of Luminex in substantially the same proportions as their ownership of stock of Luminex, or (3) a Person not less than a majority of whose voting securities are Beneficially Owned by Luminex after giving effect to the transaction.
As used in this Agreement, “ Bonus Amount ” means the earned bonus compensation as described in Paragraph 3.2 above (if any) paid or payable for the last full year for which a bonus has been paid or remains payable as provided in this Agreement.
Any options or stock appreciation rights (together, “ Options ”) granted (including without limitation Options that may be granted in the future) and restricted stock and restricted stock units (together, “ Restricted Stock ”) issued (including without limitation Restricted Stock that may be issued in the future) to Executive pursuant to any incentive plan of Luminex shall immediately vest upon a Change in Control. For the avoidance of doubt, “Performance Awards” granted pursuant to the 2006 Plan (as hereinafter defined), or any successor plan, shall vest only according to the terms of the applicable award agreement in the event of a Change in Control or otherwise. Luminex shall take no action to facilitate a transaction involving a Change in Control, including without limitation redemption of any rights issued pursuant to any rights agreement, unless it has taken such action as may be necessary to ensure that Executive has the opportunity to exercise all Options he may then hold, and obtain certificates containing no restrictive legends in respect of any Restricted Stock he may then hold, at a time and in a manner that shall give Executive the opportunity to sell or exchange the securities of Luminex acquired upon exercise of his Options and upon receipt of unrestricted certificates for shares of Common Stock in respect of his Restricted Stock, if any (collectively, the “ Acquired Securities ”), at the earliest time and in the most advantageous manner any holder of the same class of securities as the Acquired Securities is able to sell or exchange such securities in connection with such Change in Control. Luminex acknowledges that its covenants in the preceding sentence (the “ Covenants ”) are reasonable and necessary in order to protect the legitimate interests of Luminex in maintaining Executive as one of its employees and that any violation of the Covenants by Luminex would result in irreparable injuries to Executive, and Luminex therefore acknowledges that in the event of any violation of the Covenants by Luminex or its directors, officers or employees, or any of their respective agents, Executive shall be entitled to obtain from any court of competent jurisdiction temporary, preliminary and permanent injunctive relief in order to (i) obtain specific performance of the Covenants, (ii) obtain specific performance of the exercise of his Options, delivery of certificates containing no restrictive legends in respect of his Restricted Stock and the sale or exchange of the Acquired Securities in the advantageous manner contemplated above or (iii) prevent violation of the Covenants; provided nothing in this Agreement shall be deemed to prejudice Executive's rights to damages for violation of the Covenants. In the event that the terms of any




separate written agreement concerning Options granted or Restricted Stock issued to Executive conflict with the terms of this paragraph, the terms of this paragraph shall control.
3.4     Additional Benefits . During the Term, Executive shall be entitled to the following fringe benefits:

3.4.1     Benefits and Vacation . Executive shall be entitled to participate in such profit sharing, pension, retirement, deferred compensation, savings, life, medical, dental, disability and other welfare benefit plans maintained by Luminex in accordance with the terms thereof, as the same may be amended and in effect from time to time, as are now generally available or later made generally available to executive officers of Luminex. A termination or expiration of this Agreement for any reason or for no reason shall not affect any rights which Executive may have pursuant to any agreement, policy, plan, program or arrangement of Luminex providing Executive benefits (including under any stock option agreement or bonus plan or agreement which may exist), which rights shall be governed by the terms thereof. Executive shall be entitled to four (4) weeks paid vacation each calendar year (prorated for partial years); provided that Executive shall not be entitled to either (i) more than two (2) consecutive weeks of vacation or (ii) more than two (2) weeks of vacation in any rolling four (4) week period. Unless approved in advance by the Board or a committee thereof, accrued vacation not taken in any applicable period shall not be carried forward or used in any subsequent period. The Compensation Committee of the Board shall consider from time to time whether Executive’s vacation term should be increased.

3.4.2     Reimbursement for Expenses .

3.4.2.1     Incidental Expenses . Luminex shall reimburse Executive for reasonable and properly documented out-of-pocket business and/or entertainment expenses incurred by Executive in connection with his duties under this Agreement. Any such expenses shall be submitted by Executive to Luminex on a periodic basis and will be paid in accordance with standard Luminex policies and procedures.

3.4.2.2     Expenses Associated with Relocation of Executive to the Austin, Texas Area . Luminex shall reimburse Executive for any reasonable, out-of-pocket and adequately documented (i) moving expenses incurred by Executive in connection with the transfer of the contents of his residences from Atlanta, Georgia to the Austin, Texas metropolitan area; (ii) airfare incurred by Executive’s spouse in the course of making up to three (3) house-hunting trips to the Austin, Texas metropolitan area; (iii) Executive will use his best efforts to relocate himself and his family to the Austin, Texas metropolitan area as soon as reasonably possible; however in the meantime, he will be reimbursed for any reasonable, out-of-pocket and adequately documented hotel lodging, meals and related incidental expenses (e.g., laundry service) in Austin, Texas and end-of-workweek airfare to Atlanta, Georgia and commencement-of-workweek airfare to Austin, Texas (so that Executive may be at his Atlanta home on the weekends) for a period of four (4) months commencing on the Effective Date, unless Executive is able to move to a permanent residence in the Austin, Texas metropolitan area before the conclusion of such four (4) month period; (iv) rent payments of up to Five Thousand Dollars ($5,000) per month for months five (5) and six (6) subsequent to the Effective Date made by Executive in respect of renting a primary temporary residence in the Austin, Texas metropolitan area, unless Executive is able to move to a permanent residence in the Austin, Texas metropolitan area before the beginning of months five (5) or six (6), respectively; (v) real estate agency commissions (at standard rates) assessed on the sale of Executive’s residence in Atlanta, Georgia, and (vi) closing costs (including up to one “point” paid in connection with obtaining a residential mortgage) associated with the purchase of Executive’s primary permanent residence in the Austin, Texas metropolitan area. In addition to the foregoing, in consideration of the inconvenience of relocating Executive and his family, upon the purchase of Executive’s primary permanent residence in the Austin, Texas metropolitan area, Luminex shall pay Executive a one-time, lump-sum payment equal to Thirty Thousand Dollars ($30,000).

3.4.2.3     Legal Expenses . Within thirty (30) days after the execution and delivery of this Agreement by Luminex and Executive, Luminex shall reimburse Executive for all reasonable, out-of-pocket and adequately documented attorneys’ fees incurred by Executive in the course of the negotiation and documentation of this Agreement, the Restricted Stock Agreement and the Stock Option Award Agreement to be entered into between Luminex and Executive pursuant to Paragraphs 3.5 and 3.6 .

3.4.2.4     Future Moving Expenses . In the event of the relocation of Luminex’s headquarters to a location that is outside the Office Area and Executive elects to relocate, Luminex shall reimburse Executive for any reasonable, out-of-pocket, and adequately documented moving expenses incurred by Executive in connection with the transfer of his residence.





3.4.2.5     Reimbursement Payment Adjustment . In addition and as to each reimbursement payment, to the extent that any reimbursement under the clauses in Paragraphs 3.4.2.2 and 3.4.2.4 is not fully deductible by Executive for federal, state and local income tax purposes after giving effect to any phase-outs or imitations on such deductions, Luminex will pay Executive an additional amount such that the net amount retained by Executive, after deduction of any federal, state and local income tax on the reimbursement and such additional amount, will be equal to the reimbursement payment. Any such reimbursement shall be made strictly in accordance with Section 1.409A-3(i)(1)(v) of the Treasury Regulations, which is incorporated herein.

3.5     Stock Options . On the date hereof, Executive shall be awarded an option to purchase two hundred and fifty thousand (250,000) shares of Luminex’s Common Stock pursuant to Luminex’s Second Amended and Restated 2006 Equity Incentive Plan, as amended (the “ 2006 Plan ”), which shall vest in four (4) equal increments on each of the succeeding four (4) anniversaries of the date of grant.

3.6     Restricted Stock Award . On the date hereof, Executive shall be awarded one hundred thousand (100,000) shares of Luminex’s Common Stock pursuant to the 2006 Plan, which shall vest in four (4) equal increments on each of the succeeding four (4) anniversaries of the date of grant.

4. Severance Compensation .

4.1     Severance Compensation in the Event of a Termination Other Than For Cause . In the event Executive’s employment is terminated as a result of a Termination Other Than for Cause, Executive shall be paid (subject to Paragraph 4.6 ) the Severance Compensation (defined below).

4.2     Severance Compensation for Termination by Reason of Incapacity . In the event Executive’s employment is terminated as a result of a Termination by Reason of Incapacity, Executive shall be paid (subject to Paragraph 4.6 ) the Severance Compensation.

4.3     Severance Compensation for Termination by Reason of Death . In the event Executive’s employment is terminated as a result of Executive’s death, the estate of Executive shall be paid the Severance Compensation.

4.4     Severance Compensation In the Event Of A Failure Of Luminex To Renew This Agreement . In the event Luminex fails or otherwise refuses for any reason to extend this Agreement beyond the initial Term and any extensions thereof, Executive shall be paid (subject to Paragraph 4.6 ) the Severance Compensation upon his subsequent termination of employment.

4.5     No Severance Compensation Upon Other Termination . In the event of an Actual Voluntary Termination or Termination For Cause, Executive shall not be paid any severance compensation.

4.6     Conditions to Payment; Sole Remedy . Executive shall not be entitled to receive any compensation or other payment pursuant to Paragraphs 4.1 , 4.2 or 4.4 unless Executive shall have executed and delivered to Luminex a mutual release, prepared and signed by Luminex in substantially in the form attached hereto as Exhibit A (the “ Release ”) following receipt of such Release from Luminex and all revocation and waiting periods required by applicable law and applicable to such Release have expired, in each case, prior to the expiration of the Severance Delay Period (as defined below). If Luminex fails to deliver to Executive the signed Release at least thirty (30) days prior to the expiration of the Severance Delay Period (as defined below), then Executive’s requirement to execute and deliver to Luminex the Release pursuant to this Paragraph 4.6 shall become null and void. In addition, in the event that Executive breaches any of the restrictive covenants set forth in Article 5 at any time, Luminex shall be entitled to discontinue any compensation or other payments pursuant to Paragraphs 4.1 , 4.2 or 4.4 (provided, however, that if it is finally determined by a court of competent jurisdiction in a final judgment not subject to further appeal, that Luminex asserted in bad faith that Executive breached any of the restrictive covenants set forth in Article 5 , the payments of the Severance Compensation shall be extended for two months for each calendar month that payments were delayed). The compensation to be paid to Executive pursuant to Paragraphs 4.1 , 4.2 , 4.3 or 4.4 shall represent the sole and exclusive remedy of Executive in connection with the termination of his employment and this Agreement upon a Termination Other Than for Cause, a Termination by Reason of Incapacity, a termination in connection with Executive's death, or a refusal by Luminex to extend this Agreement beyond the Term and any extensions thereof. In the event that Luminex shall terminate Executive for Cause, Executive shall not be eligible to receive any compensation or other payment pursuant to Paragraphs 4.1 , 4.2 or 4.4 and Executive shall not be required to sign the Release. For purposes of this Agreement, “ Severance Delay Period ” means the sixty (60) day period immediately following the Executive's termination date. The Executive acknowledges that his failure to timely




execute and return the Release or the failure of all revocation periods to end prior to the expiration of the Severance Delay Period will result in his forfeiture of the Severance Compensation.

4.7     Definition of Severance Compensation . As used in this Agreement, “ Severance Compensation ” means an amount equal to the sum of (i) the Bonus Amount, plus (ii) an amount equal to the greater of (A) Executive's annual Base Salary (at the highest rate in effect for the six month period immediately prior to the date of termination) or (B) the amount of Base Salary that would have been paid to Executive over the remainder of the Term, assuming that Luminex would have provided Executive with written notice of Luminex's intent not to renew this Agreement in accordance with Paragraph 2.1 . The Severance Compensation shall be paid in semi-monthly installments for a period of twelve (12) months from the date of termination (the “ Severance Period ”). Notwithstanding the foregoing, the payment of Severance Compensation under Paragraphs 4.1 , 4.2 and 4.4 shall commence on the 60th day following Executive's termination date (the “ Initial Payment Date ”) and Severance Compensation scheduled to be made during the Severance Delay Period shall be accrued and paid on the Initial Payment Date with any remaining Severance Compensation continuing for the remainder of the Severance Period hereunder. In addition, as part of the Severance Compensation, Luminex also shall pay: (i) (until the earlier of (x) the first annual anniversary of the termination of this Agreement or (y) the date that Executive is eligible to be covered under a comparable or more favorable health plan of another Person) (A) COBRA payments in respect of the continuation of health benefits for Executive, his spouse and his children and (B) COBRA payments to fund dental and vision coverage for Executive, his spouse and his children comparable to the dental and vision coverage provided to other employees of Luminex; and (ii) subject to the restrictions and obligations related to the Severance Compensation set forth herein, on the Initial Payment Date to Executive a lump sum amount equal to the sum of (A) Luminex’s annual cost for the Executive’s short-term and long-term disability and life insurance in effect on the date of the Executive’s termination of employment and (B) the amount of the contribution for the Executive under Luminex’s 401(k) Retirement Plan for the plan year prior to the year of the Executive’s termination of employment.  Notwithstanding the foregoing, if the Company making any payment pursuant to the foregoing sentence would violate the nondiscrimination rules applicable to non-grandfathered plans, or result in the imposition of penalties under, the Patient Protection and Affordable Care Act of 2010 (“PPACA”) and related regulations and guidance promulgated thereunder, the parties agree to reform such sentence in such manner as is necessary to comply with PPACA.

4.8     Section 409A .

4.8.1    It is intended that that the payments under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Section 409A of the Code, including those provided under Treasury Regulations 1.409A-1(b)(4) (regarding short-term deferrals), 1.409A-1(b)(9)(iii) (regarding the two-times, two (2) year exception) and 1.409A-1(b)(9)(v) (regarding reimbursements and other separation pay). Notwithstanding anything to the contrary herein, if (i) on the date of Executive's “separation from service” (as such term is defined under Treasury Regulation 1.409A-1(h)), Executive is deemed to be a “specified employee” (as such term is defined under Treasury Regulation 1.409A-1(i)(1)) of Luminex, as determined in accordance with Luminex's “specified employee” determination procedures, and (ii) any payments to be provided to Executive pursuant to this Agreement which constitute “deferred compensation” for purposes of Section 409A of the Code and are or may become subject to the additional tax under Section 409A(a)(1)(B) of the Code or any other taxes or penalties imposed under Section 409A of the Code if provided at the time otherwise required under this Agreement, then such payments shall be delayed until the date that is six (6) months after the date of Executive's “separation from service” (as such term is defined under Treasury Regulation 1.409A-1(h)) or, if sooner, the date of Executive's death. Any payments delayed pursuant to this Paragraph 4.8.1 shall be made in a lump sum on the first day of the seventh month following Executive's “separation from service” (as such term is defined under Treasury Regulation 1.409A-1(h)) or, if sooner, the date of Executive's death and any remaining payments shall be paid according to the schedule otherwise applicable to the payments.

4.8.2    Notwithstanding any other provision to the contrary, a termination of employment with Luminex shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of “deferred compensation” (as such term is defined in Section 409A of the Code and the Treasury Regulations promulgated thereunder) upon or following a termination of employment unless such termination is also a “separation from service” from Luminex within the meaning of Section 409A of the Code and Section 1.409A-1(h) of the Treasury Regulations and, for purposes of any such provision of this Agreement, references to a “separation,” “termination,” “termination of employment” or like terms shall mean “separation from service.”

4.8.3    To the extent that any expenses, reimbursement, fringe benefit or other, similar plan or arrangement in which Executive participates during the term of Executive's employment under this Agreement (including any reimbursements under Paragraphs 3.4.2.1 , 3.4.2.2 , 3.4.2.4 , 3.4.2.5 7 or 8.5 hereof) or thereafter provides for a “deferral of compensation” within the meaning of Section 409A of the Code, then such amount shall be reimbursed in accordance with Section 1.409A-3(i)(1)(iv) of the Treasury Regulations (or Section 1.409A-3(i)(1)(v) of the Treasury Regulations, as applicable),




including (i) the amount eligible for reimbursement or payment under such plan or arrangement in one calendar year may not affect the amount eligible for reimbursement or payment in any other calendar year (except that a plan providing medical or health benefits may impose a generally applicable limit on the amount that may be reimbursed or paid), (ii) subject to any shorter time periods provided herein or the applicable plans or arrangements, any reimbursement or payment of an expense under such plan or arrangement must be made on or before the last day of the calendar year following the calendar year in which the expense was incurred, and (iii) the right to any reimbursement or in-kind benefit is not subject to liquidation or exchange for another benefit.

4.8.4    Notwithstanding any other provision to the contrary, in no event shall any payment under this Agreement that constitutes “deferred compensation” for purposes of Section 409A of the Code and the Treasury Regulations promulgated thereunder be subject to offset by any other amount unless otherwise permitted by Section 409A of the Code.

5. Protection of Luminex .

5.1     Non-Competition . Ancillary to the otherwise enforceable agreements set forth in this Agreement, Executive agrees that during Executive’s employment with Luminex and for a period of two (2) years following termination of employment, whether such termination occurs at the insistence of Executive or Luminex for any reason, Executive shall not compete directly or indirectly in any way with the business of Luminex anywhere in the world where Luminex conducted business during the Term. For purposes of this Agreement, “compete directly or indirectly in any way with the business of Luminex” means to become an employee, consultant, advisor, manager, member, director of or beneficially own more than three percent of any individual, company or entity that is engaged in biological testing technology using multiplexing and/or real-time PCR with application to the life-sciences industry at the time of determination (the “ Core Business ”). Executive agrees that the assertion or existence of any claim by Executive against Luminex shall not be a defense to the enforcement of this paragraph by injunction or otherwise.

5.2     Nonsolicitation . Ancillary to the otherwise enforceable agreements set forth in this Agreement, Executive agrees that, for a period of two (2) years subsequent to the termination of Executive’s employment with Luminex, whether such termination occurs at the insistence of Executive or Luminex for any reason, Executive shall not recruit, hire, or attempt to recruit or hire, directly or by assisting others, any other employees of Luminex, nor shall Executive contact or communicate with any other employees of Luminex for the purpose of inducing other employees to terminate their employment with Luminex. The foregoing shall not apply to (a) general public or industry solicitations not targeted at employees of Luminex, (b) solicitations in which Executive is not materially involved that are not targeted at employees of Luminex, for example by third party recruiters or staffing agencies, or by a third party company’s human resources or other department which is hiring in the ordinary course of business and where Executive is not materially involved in the recruiting process and that are not specifically targeted at employees of Luminex and (c) any Luminex employee who, on their own volition and without inducement, approaches a third party company with which Executive may be affiliated in the future. For purposes of this covenant, “other employees of Luminex” shall refer to (i) employees who are still actively employed by Luminex or a subsidiary of Luminex at the time of the attempted recruiting or hiring and (ii) individuals who were employed by Luminex or a subsidiary of Luminex within six (6) months prior to the time of the attempted recruiting or hiring.

5.3     Remedies . Due to the irreparable and continuing nature of the injury which would result from a breach of the covenants described in Paragraphs 5.1 and 5.2 , Executive agrees that Luminex may, in addition to any remedy which Luminex may have at law or in equity, apply to any court of competent jurisdiction for the entry of an immediate order to restrain or enjoin the breach of this covenant and to otherwise specifically enforce the provisions of the covenants set forth in Paragraphs 5.1 and 5.2 .

5.4     Acknowledgment . Executive acknowledges and agrees that the restrictions set forth above are ancillary to an otherwise enforceable agreement and supported by independent valuable consideration as required by TEX. BUS. & COMM. CODE ANN. § 15.50. Executive further acknowledges and agrees that the limitations as to time, geographical area, and scope of activity to be restrained by Paragraphs 5.1 and 5.2 are reasonable and acceptable to Executive, and do not impose any greater restraint than is reasonably necessary to protect the goodwill and other business interests of Luminex.

5.5     Reformation and Severance . If a judicial determination is made that any of the provisions of the above restriction constitutes an unreasonable or otherwise unenforceable restriction against Executive, it shall be rendered void only to the extent that such judicial determination finds such provisions to be unreasonable or otherwise unenforceable. In this regard, the parties hereby agree that any judicial authority construing this Agreement shall be empowered to sever any portion of the prohibited business activity from the coverage of this restriction and to apply the restriction to the remaining portion of the business activities not so severed by such judicial authority. Moreover, notwithstanding the fact that any provisions of this




restriction are determined by a court not to be specifically enforceable through injunctive relief, Luminex shall nevertheless be entitled to seek to recover monetary damages as a result of the breach of any provision which is found enforceable or reformed to be enforceable by a court. The time period during which the restrictions shall apply shall be tolled and extended as to Executive for a period equal to the aggregate quantity of time during which a court of competent jurisdiction has held that Executive has violated such prohibitions in any respect.

5.6     Confidential Information and Trade Secrets . As used herein, “ Confidential Information ” means any data or information that is important, competitively sensitive, and not generally known by the public or persons involved in the biological testing or life sciences industries, including, but not limited to, Luminex’s business plans, prospective customers, training manuals, proprietary software, product development plans, bidding and pricing procedures, market plans and strategies, projections, internal performance statistics, financial data, confidential personnel information concerning employees of Luminex, operational or administrative plans, policy manuals, and terms and conditions of contracts and agreements. The term “Confidential Information” shall not apply to information which is (i) already in Executive’s possession (unless such information was obtained by Executive from Luminex in the course of Executive’s employment by Luminex); (ii) received by Executive from a third party with, to Executive’s knowledge, no restriction on disclosure and who lawfully obtained such information; (iii) required to be disclosed by any applicable law or by an order of a court of competent jurisdiction; (iv) otherwise released by Luminex in a non-confidential manner; or (v) in lawful possession of a third party not under an obligation of confidentiality to Luminex.

Executive recognizes and acknowledges that the Confidential Information constitutes valuable, special and unique assets of Luminex and its affiliates. Except as required to perform Executive’s duties as an Executive of Luminex, until such time as it ceases to be Confidential Information through no act of Executive in violation of this Agreement, Executive will not use or disclose any Confidential Information of Luminex. Upon the request of Luminex and, in any event, upon the termination of this Agreement for any reason, Executive will surrender to Luminex (i) all memoranda, notes, records, drawings, manuals or other documents pertaining to Luminex’s business including all copies and/or reproductions thereof and (ii) all materials involving any Confidential Information of Luminex.
5.7     Preservation of Luminex Property . Executive acknowledges that from time to time in the course of employment with Luminex, Executive will have the opportunity to inspect and use certain property of Luminex, both tangible and intangible, including but not limited to files, records, documents, drawings, specifications, lists, equipment, graphics, designs, and similar items relating to the business of Luminex. Executive acknowledges and agrees that all such property, including but not limited to any and all copies thereof, whether prepared by Executive or otherwise in the possession of Executive, are and shall remain the exclusive property of Luminex, that Executive shall have no right or proprietary interest in such property and that Executive will safeguard and return to Luminex all such property upon the earlier of (i) Luminex’s request and (ii) the termination of Executive’s employment with Luminex.

5.8     Assignment of Inventions to Luminex; Work for Hire; Cooperation.

5.8.1    Luminex shall own all right, title and interest (including all patent, copyright, trademark, trade secret, database rights, and all other rights of any sort throughout the world) in and to any and all inventions (whether or not patentable) works of authorship, works, developments, discoveries, methods, processes, designs, ideas, concepts, information, improvements and/or other work product made, caused to be made, conceived, implemented or reduced to practice, in whole or in part, whether alone or acting with others, by Executive during the term of Executive’s employment with Luminex (collectively, “ Inventions ”).  Executive agrees to promptly disclose all Inventions to Luminex, and Executive agrees to hold in confidence and not disclose any Invention to any third party.  Executive further agrees that all Inventions are “works made for hire” within the meaning of the Copyright Act of 1976, as amended, are the sole and exclusive property of Luminex, and Executive shall have no right to exercise any economic rights to any Invention.  Executive hereby irrevocably assigns, transfers, and sets over absolutely, without further consideration, to Luminex any and all rights, title, and interest in and to all Inventions; provided however, that this Paragraph shall not apply to any Invention for which no equipment, supplies, facilities, intellectual property, trade secrets or Confidential Information of Luminex were used and that was developed entirely on Executive’s own time, unless the Invention (i) relates to Luminex’s current or contemplated business or activities; (ii) relates to Luminex’s actual or demonstrably anticipated research or development; or (iii) results from or relates to any work performed by Executive for Luminex.  To the extent Executive uses or discloses his confidential or proprietary information or intellectual property that does not constitute Inventions when acting within the scope of Executive’s employment or otherwise on behalf of Luminex, Luminex will have, and Executive hereby grants to Luminex, a perpetual, irrevocable, worldwide, royalty-free, non-exclusive, sublicensable right and license to exploit, exercise and otherwise use such confidential or proprietary information and/or intellectual property.





5.8.2    Executive agrees to perform, upon the reasonable request of Luminex, during or after Executive’s employment with Luminex, such further acts as may be necessary or desirable to confirm, transfer, perfect, and defend Luminex’s ownership of any Invention, including without limitation: (a) executing, acknowledging, and delivering any requested affidavits and documents of assignment and conveyance; (b) assisting in the preparation, prosecution, procurement, maintenance and enforcement of all copyrights, patents and/or other rights with respect to any Invention in any country; (c) providing testimony in connection with any proceeding affecting the right, title or interest of Luminex in any Invention; and/or (d) performing any other acts Luminex deems necessary to carry out the purposes of this Agreement.  Luminex shall reimburse all reasonable, actual, out-of-pocket expenses incurred by Executive at Luminex’s request in connection with the foregoing. In the event that Luminex requests Executive’s signature under clause 5.8.2(a) - (c) above and Executive fails or refuses to do so within a reasonable time, then it shall be deemed that Executive has irrevocably designated and appointed Luminex as Executive’s agent and attorney-in-fact, coupled with an interest, to act for and on Executive’s behalf to execute and file any document and to do all other lawfully permitted acts to further the foregoing with the same legal force and effect as if executed by Executive; provided, however, that this grant of power by Executive to Luminex shall not authorize Luminex to undertake in Executive’s name any improper, illegal, fraudulent, misleading, or unethical act.

5.9     Notice to Subsequent Employers . Executive agrees that, prior to commencing any new employment in the Core Business within twenty-four (24) months after the termination of this Agreement (as extended on a day-for-day basis pursuant to the last sentence of Paragraph 5.5 ), Executive will notify Luminex and furnish the new employer with a copy of this Agreement. Executive also agrees that Luminex may advise any new or prospective employer of the existence and terms of this Agreement and furnish the employer with a copy of this Agreement for a period not to exceed (24) months after the termination of this Agreement (as extended on a day-for-day basis pursuant to the last sentence of Paragraph 5.5 ).

5.10     Attorney’s Fees . Luminex and Executive agree that the prevailing party will be entitled to recover its attorney’s fees in connection with any action or proceeding Luminex institutes to enforce any restriction set forth in this Article 5 .

6. Disclosure of Investments . Commencing upon Executive’s execution of this Agreement and at all times during the Term, Executive shall keep the Board informed in writing of the nature and extent of Executive’s investments, stock holdings, or retention as a director, advisor or any similar interest in any business or enterprise involved in the Core Business other than Luminex; provided, however, that Executive shall not be required to disclose (i) any such investments or stock holdings that constitute less than 1% of such entity’s total obligations or total voting power; (ii) any interest in a publicly available mutual fund that has such a business as part of its portfolio; or (iii) any interest held in a blind trust or professionally managed portfolio where Executive does not exercise trading discretion.

7. Indemnification . Luminex hereby agrees that it shall defend, indemnify and hold harmless Executive to the fullest extent permitted by law from and against any and all demands, liabilities, costs, claims and expenses, including all reasonable costs and expenses incurred in defense of litigation (including reasonable attorneys’ fees), arising out of the employment of Executive hereunder, or Executive’s service on the Board, except to the extent an arbitrator or court of competent jurisdiction holds in a final judgment not subject to further appeal that it arose out of or was based upon (i) the gross negligence or willful misconduct of Executive or (ii) a breach of any of Executive’s agreements, covenants, representations or warranties under or in connection with this Agreement. Costs and expenses incurred by Executive in defense of such litigation (including reasonable attorneys’ fees) shall be paid by Luminex in advance of the final disposition of such litigation upon receipt by Luminex of (i) a written request for payment; (ii) appropriate documentation evidencing the incurrence, amount and nature of the costs and expenses for which payment is being sought; and (iii) an undertaking adequate under applicable law made by or on behalf of Executive to repay the amounts so paid if it shall ultimately be determined that Executive is not entitled to be indemnified by Luminex under this Agreement, including but not limited to as a result of such exception. Luminex and Executive will consult in good faith with respect to the conduct of any such litigation, and Executive’s counsel shall be selected with the consent of Luminex.

8. Arbitration .

8.1     Exclusive Remedy . Arbitration shall be the sole and exclusive remedy for resolving any claim or dispute relating to the interpretation or application of this Agreement which cannot be mutually resolved between the parties to this Agreement with the exception of disputes arising out of Executive’s obligations under Article 5 or disputes arising out of Luminex’s obligations under the last paragraph of Paragraph 3.3 , which are not subject to this arbitration provision; provided however, that the parties hereto agree that disputes arising out of or relating to the enforceability, revocability or validity of the Agreement, may be determined only by a court of competent jurisdiction and not by an arbitrator.   Except as otherwise provided, the parties hereto agree that the Agreement applies, without limitation, to disputes regarding termination, interpretation, or




application of this Agreement or any other agreement or policy of Luminex, to disputes regarding the employment relationship, trade secrets, unfair competition, compensation, breaks and rest periods, termination, retaliation, discrimination, harassment, claims arising under the Civil Rights Act of 1964, Americans With Disabilities Act, Age Discrimination in Employment Act, Family Medical Leave Act,  and Fair Labor Standards Act, claims arising under the Uniform Trade Secrets Act, claims arising under the Employment Retirement Income Security Act (“ ERISA ”) (except for claims for employee benefits under any benefit plan sponsored by the hospital and covered by the ERISA or funded by insurance), and Genetic Information Non-Discrimination Act, claims arising under any other federal and all state statutes, and common law claims, if any, addressing the same or similar subject matters, or any claim by Luminex against Executive.  This Agreement is a waiver of the right to trial by a jury or court.

8.2     Limitations . The request for arbitration must be made within one (1) year from the date of the occurrence giving rise to the dispute or claim; or, in the event of a statutory claim, the time set forth by statute.

8.3     Rules and Procedures . The arbitration will be conducted under the rules and procedures for arbitration of employment disputes of the American Arbitration Association. The arbitration shall take place in Austin, Texas unless the parties mutually agree to another location.

8.4     Arbitrator’s Authority . Upon finding that a claim is meritorious or in favor of one of the parties to the dispute, the arbitrator or arbitrators shall have the authority to order legal and equitable remedies appropriate as permitted by law.

8.5     Expenses . Costs of obtaining and paying the arbiter and the costs associated with conducting the arbitration, including obtaining a facility to be used during the arbitration, shall be paid by Luminex if Executive is the prevailing party. If Executive is the prevailing party, Luminex shall reimburse Executive for all other reasonable costs of the arbitration or any litigation associated with any dispute arising under or in connection with this Agreement, including without limitation, reasonable attorneys’ and experts’ fees and expenses incurred by Executive, provided, however, that the obligation of Luminex under this sentence shall not apply insofar as the arbitration or litigation concerns matters in respect of which Luminex is prohibited from indemnifying Executive under Delaware or any other applicable law.

9. Representations and Warranties . As a material inducement to Executive entering into this Agreement, the accuracy of which Executive is relying upon for purposes of entering into this Agreement and performing the terms hereof, Luminex makes the following representations and warranties to Executive, which shall be true and correct as of the Effective Date: (a) the execution, delivery and performance of this Agreement by Luminex does not violate any applicable law or regulation, whether federal, state, local or international, or any order, judgment or decree; (b) Luminex has obtained all necessary approvals to enter into this Agreement with Executive and perform the terms hereof; and (c) with regard to all matters pertaining to the business of Luminex for which the statutory period of limitations has not yet expired, to its actual knowledge, Luminex has conducted its business and affairs in material compliance with applicable law and regulations.

10. Miscellaneous .

10.1     Waiver . The waiver of the breach of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach of the same or other provision hereof.

10.2     Entire Agreement; Modifications . Except as otherwise provided herein, including the ancillary documents referenced herein, this Agreement represents the sole, entire, and complete understanding among the parties with respect to the subject matter hereof, and this Agreement supersedes any and all prior understandings, agreements, plans and negotiations, whether written or oral, with respect to the subject matter hereof, including without limitation any understandings, agreements or obligations respecting any past or future compensation, bonuses, reimbursements or other payments to Executive from Luminex. All modifications to the Agreement must be in writing and signed by both Executive and Luminex.

10.3     Notices . All notices and other communications under this Agreement shall be in writing and shall be given by transmission of the item in portable document format (pdf) via electronic mail or first class mail, certified or registered with return receipt requested, or by generally recognized overnight courier providing next business day delivery (such as FedEx or UPS) and shall be deemed to have been duly given three (3) business days after mailing if by first class mail, the date of delivery if by courier or one business day after electronic mail transmission of a pdf (provided that to be valid, the electronic mail transmission must be followed-up on the next business day by the dispatch of a mailing either by first class mail or by courier) to the respective persons named below:




If to Luminex:
Luminex Corporation
 
12212 Technology Blvd.
 
Austin, Texas 78727
 
E-mail: dreiter@luminexcorp.com
 
Attn: General Counsel and Corporate Secretary
 
 
With a copy to
Bass, Berry & Sims PLC
 
150 Third Avenue South
 
Suite 2800
 
Nashville, Tennessee 37201
 
E-mail: hlamar@bassberry.com
 
Attn: Howard H. Lamar III
 
 
If to Executive:
Notices to Executive shall be given at the most recent address of Executive on the records on Luminex

Any party may change such party’s address for notices by notice duly given pursuant to this Paragraph 10.3 .
10.4     Headings . The Paragraph headings herein are intended for reference and shall not by themselves determine the construction or interpretation of this Agreement.

10.5     Governing Law; Venue . This Agreement shall be governed by and construed in accordance with the laws of the State of Texas. Subject in all respects to Paragraph 8 generally and Paragraph 8.3 in particular, any dispute arising out of or relating to this Agreement may be brought in a court of competent jurisdiction located in Austin, Texas, and both of the parties to this Agreement irrevocably submit to the exclusive jurisdiction of such courts in any such dispute, waives any objection it may now or hereafter have to venue or to convenience of forum, agrees that all claims in respect of the dispute shall be heard and determined only in any such court, and agrees not to bring any dispute arising out of or relating to this Agreement in any other court. The parties agree that either or both of them may file a copy of this paragraph with any court as written evidence of the knowing, voluntary and bargained agreement among the parties irrevocably to waive any objections to venue or to convenience of forum. Process in any dispute may be served on any party anywhere in the world.

10.6     Severability . Should any court of competent jurisdiction determine that any provision of this Agreement is illegal or unenforceable to any extent, such provision shall be enforced to the extent permissible and all other provisions of this Agreement shall continue to be enforceable to the extent possible.

10.7     Counterparts . This Agreement may be executed in one or more counterparts, all of which taken together shall constitute one and the same Agreement.

10.8     Assignment . Neither this Agreement nor any duties or obligations hereunder may be assigned by either party without the other party’s prior written consent; provided, however, that Luminex may assign this Agreement to either (i) a wholly-owned subsidiary of Luminex (provided, however, that such assignment shall not relieve Luminex of its obligations hereunder) or (ii) a Person acquiring substantially all of Luminex’s assets if such acquisition would constitute a Change in Control.

10.9     Withholding . All compensation and benefits payable to Executive hereunder shall be reduced by all federal, state, local and other withholdings and similar taxes and payments required by applicable law.

[ Remainder of page intentionally left blank. Signature page follows ]







IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.
 
 
 
 
LUMINEX CORPORATION
 
 
 
 
/s/ David S. Reiter
 
By:
David S. Reiter
 
Its:
General Counsel and Senior Vice President
 
 
 
 
 
 
 
 
 
 
EXECUTIVE
 
 
 
 
/s/ Nachum Shamir
 
Nachum Shamir



Signature Page to Employment Agreement by and between Luminex Corporation and Nachum Shamir



Exhibit A


GENERAL RELEASE AGREEMENT


THIS GENERAL RELEASE AGREEMENT (this “Agreement”) dated as of this __ day of ______, 20__ [fill in effective date of termination pursuant to the Employment Agreement] (the “Effective Date”), is by and between Nachum Shamir (“Executive”) and Luminex Corporation (“Luminex”).

WHEREAS, Executive’s employment with Luminex has terminated pursuant to that certain Employment Agreement dated as of October 14, 2014 (the “Employment Agreement”).

NOW, THEREFORE, in consideration of the foregoing premises and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

1.     Termination of Employment . Executive and Luminex hereby agree that Executive’s employment with Luminex has terminated pursuant to Section __ [fill in applicable section] of the Employment Agreement effective as of the Effective Date. To the extent he continues to hold any such positions or directorships, Executive hereby resigns all positions and directorships he holds with Luminex and any and all of Luminex’s subsidiaries and affiliates.

2.     Release by Executive . Executive, on his own behalf and on behalf of the Executive Released Parties (defined below), hereby irrevocably and unconditionally releases and forever discharges Luminex, its subsidiaries and other affiliates and their respective agents, employees, representatives, officers, directors, stockholders, trustees and attorneys, past and present, and the heirs, successors and assigns of all of the foregoing (collectively, the “Released Parties”) from any and all debts, liabilities, claims, demands, actions or causes of action, suits, judgments or controversies of any kind whatsoever (except as set forth below) arising from Executive’s relationship (including without limitation as a stockholder) to, employment with or service as an employee, officer, director, or manager of Luminex or its subsidiaries and affiliates, or the termination of any such relationships (collectively, the “Claims”) against the Released Parties, that now exist or that may arise in the future out of any matter, transaction or event occurring prior to or on the Effective Date, including without limitation, any claims of breach of contract or for severance or other termination pay (except as set forth in Section 4 below), or claims of unlawful retaliation, harassment or discrimination or denial of some benefit or protection accorded to Executive (for example, on the basis of age, sex, race, handicap, disability, religion, color or national origin, or for complaining of such) under any federal, state or local law, rule or regulation, including, but not limited to the Age Discrimination in Employment Act of 1967, 29 U.S.C. Section 621 , et seq, Title VII of the Civil Rights Act of 1964, as amended, the Employee Retirement Income Security Act (ERISA), the Worker Adjustment and Retraining Notification Act of 1988 (WARN), the National Labor Relations Act (NLRA), and/or the Fair Labor Standards Act (FLSA), the Americans with Disabilities Act (ADA), the Genetic Information Nondiscrimination Act (GINA), and/or the Family and Medical Leave Act (FMLA). Except as set forth below, Executive further agrees not to file or bring any claim, suit, civil action, complaint, arbitration or administrative action (any of the foregoing, an “Action”) in any city, state or federal court or agency or arbitration tribunal with respect to any Claim against any of the Released Parties or (except as may be required by law) assist any other person or entity with any Action against any of the Released Parties. Notwithstanding anything to the contrary contained in this Agreement, Executive does not release any of the Released Parties and shall not be prohibited from filing or bringing an Action with respect to any right Executive otherwise may have now or in the future (i) to receive distributions or dividends made in respect of Luminex’s capital stock or (ii) to be indemnified by Luminex under the Certificate of Incorporation or Bylaws of Luminex (as the same are currently in effect), any resolution adopted by the Board of Directors of Luminex, or any other separate written agreement or instrument requiring Luminex to indemnify Executive or (iii) to receive workers’ compensation claims or (iv) to receive Accrued Obligations (as such term is defined in the Employment Agreement) or (v) to receive Severance Compensation (as such term is defined in the Employment Agreement) or (vi) to stock, options, and other equity-based compensation that vested prior to the Effective Date or that vests subsequent to the Effective Date pursuant to the Employment Agreement or an applicable Luminex long-term incentive plan (which stock, options or other equity-based compensation shall be governed by the terms and provisions of the applicable written agreement(s) or instrument(s) and/or the applicable Luminex incentive plan) or (vii) to vested benefits payable under retirement and other employee benefit plans covering Executive (which benefits shall be governed by the terms and provisions of the applicable plan).

3.     Release by Luminex . Luminex, on its own behalf and on behalf of the Released Parties, hereby irrevocably and unconditionally releases and forever discharges Executive and his heirs, successors and assigns (collectively, the “Executive Released Parties”) from any and all Claims against the Executive Released Parties, that now exist or that may arise in the future. Except as set forth below, Luminex further agrees not to file or bring any Action in any city, state or federal court or agency or




arbitration tribunal with respect to any Claim against any of the Executive Released Parties or (except as may be required by law) assist any other person or entity with any Action against any of the Executive Released Parties. Notwithstanding anything to the contrary contained in this Agreement, Luminex does not release any of the Executive Released Parties and shall not be prohibited from filing or bringing an Action with respect to (i) a breach by Executive after the Effective Date of any of Executive’s obligations under the Employment Agreement that by their terms survive termination of the Employment Agreement, including without limitation the provisions of Article 5 of the Employment Agreement, or (ii) in connection with any claim for indemnification by Executive, any obligation or burden of proof applicable to Executive that is a condition to Executive’s right to be indemnified by Luminex under the Certificate of Incorporation or Bylaws of Luminex (as the same are currently in effect), any resolution adopted by the Board of Directors of Luminex, or any other separate written agreement or instrument requiring Luminex to indemnify Executive or (iii) any Claims that arise out of any criminal or fraudulent activity, willful misconduct or gross negligence of Executive.

4.     Severance Compensation . In consideration of Executive’s execution of this Agreement, Executive shall be entitled to receive from Luminex the Severance Compensation under Section __ [fill in applicable section] in the Employment Agreement. Executive acknowledges that no other promise or agreements of any kind have been made to Executive or with Executive by any person or entity whatsoever to cause Executive to sign this Agreement. Executive further acknowledges and agrees that the Severance Compensation, together with any other payments or benefits that may be due under the terms of the Employment Agreement, shall constitute full accord and satisfaction of all obligations, including without limitation any and all severance obligations, in connection with Executive’s employment. Executive would not be entitled to receive the Severance Compensation but for Executive’s execution of this Agreement.

5.     Disclaimer of Liability . Executive acknowledges that this Agreement shall not in any way be construed as an admission by Executive or any of the Released Parties of any wrongful or illegal act against the other or any other person, and that Executive and the Released Parties expressly disclaim any liability of any nature whatsoever arising from or related to the subject of this Agreement.

6.     COMPETENCY . EXECUTIVE ACKNOWLEDGES THE FOLLOWING:

(a)
THAT HE FULLY COMPREHENDS AND UNDERSTANDS ALL OF THE TERMS OF THIS AGREEMENT AND THEIR LEGAL EFFECTS;

(b)
THAT HE IS COMPETENT TO EXECUTE THIS AGREEMENT;

(c)
THAT IT IS EXECUTED KNOWINGLY AND VOLUNTARILY AND WITHOUT RELIANCE UPON ANY STATEMENT OR REPRESENTATION OF ANY RELEASED PARTY OR ITS REPRESENTATIVES;

(d)
THAT HE HAS BEEN ADVISED IN WRITING TO CONSULT WITH AN ATTORNEY BEFORE EXECUTING THIS AGREEMENT AND THAT HE HAS HAD THE OPPORTUNITY TO CONSULT WITH AN ATTORNEY OF HIS CHOICE REGARDING THIS AGREEMENT;

(e)
THAT EXECUTIVE DOES NOT WAIVE RIGHTS OR CLAIMS THAT MAY ARISE AFTER THE DATE THIS AGREEMENT IS EXECUTED;

(f)
THAT EXECUTIVE WAIVES RIGHTS OR CLAIMS UNDER THIS AGREEMENT ONLY IN EXCHANGE FOR CONSIDERATION IN ADDITION TO ANYTHING OF VALUE TO WHICH THE EXECUTIVE WAS ALREADY ENTITLED;

(g)
[THAT HE HAS BEEN PROVIDED THE MATERIALS REGARDING THE CLASS, UNIT OR GROUP OF INDIVIDUALS ELIGIBLE FOR THIS COMPENSATION AND THE TIME LIMITS APPLICABLE TO SUCH PROGRAM;] [This clause to be included if required by or advisable under applicable law.]

(h)
[THAT HE HAS BEEN PROVIDED THE JOB TITLES AND AGES OF ALL INDIVIDUALS ELIGIBLE OR SELECTED FOR THE PROGRAM AND THE AGES OF ALL INDIVIDUALS IN THE SAME JOB CLASSIFICATION OR ORGANIZATIONAL UNIT WHO ARE NOT ELIGIBLE OR SELECTED FOR THE PROGRAM;] [This clause to be included if required by or advisable under applicable law.]





(i)
THAT HE HAS HAD A PERIOD OF AT LEAST 21 [or 45 days, if required by or advisable under applicable law] DAYS WITHIN WHICH TO CONSIDER THIS AGREEMENT;

(j)
THAT FOR A PERIOD OF SEVEN DAYS FOLLOWING THE EXECUTION OF THIS AGREEMENT, EXECUTIVE MAY REVOKE THIS AGREEMENT AND IT SHALL NOT BECOME EFFECTIVE OR ENFORCEABLE UNTIL THE SEVEN-DAY PERIOD HAS EXPIRED OR SUCH LATER DATE AS PROVIDED FOR HEREIN.

7.     Parties in Interest . This Agreement is for the benefit of the Released Parties and shall be binding upon Executive and his representatives and heirs.

8.     Governing Law . This Agreement and the rights and obligations of Executive hereunder shall be governed by and construed and enforced in accordance with the substantive laws of the State of Texas.

9.     Amendment . This Agreement may not be clarified, modified, changed or amended except in writing and signed by Executive and Luminex or a successor-in-interest of Luminex.

10.     Non-disparagement . Executive agrees that he will refrain from speaking ill of or making any disparaging comment about Luminex or Luminex’s management, other employees or contractors, following the termination of his employment except as may be necessary or advisable, in the reasonable judgment of Executive, to enforce his rights under this Agreement, enforce claims arising after the Effective Date and not released in this Agreement, or defend a legal action brought against Executive by any of the Released Parties. Luminex agrees that it will refrain from speaking ill of or making any disparaging comment about Executive following the termination of his employment except as may be necessary or advisable, in the reasonable judgment of Luminex, to (i) to enforce its rights under the Employment Agreement or this Agreement not released in this Agreement or (ii) defend a legal action brought against any of the Released Parties by Executive or (iii) comply with applicable securities laws or protect Luminex from potential liability.

11.     Enforcement of Laws . Nothing in this Agreement affects the rights and responsibilities of the Equal Employment Opportunity Commission (the “Commission”) to enforce the anti-discrimination laws, and this waiver does not affect Executive’s right to file a charge or participate in an investigation or proceeding with the Commission. However, Executive waives any rights or claims, known or unknown, to participate in any recovery under any proceeding or investigation by the Commission or any state or local commission concerned with the enforcement of anti-discrimination laws. In accordance with 29 C.F.R. § 1625.23(b), nothing within this Agreement is intended to preclude Executive from bringing a lawsuit to challenge the validity of the release language contained in this Agreement with respect to a claim under the Age Discrimination in Employment Act.

12.     Severability . If any provision of this Agreement is held to be illegal, invalid or unenforceable under present or future laws, such provision shall be fully severable and this Agreement shall be construed and enforced as if such illegal, invalid or unenforceable provision never comprised a part hereof; and the remaining provisions hereof shall remain in full force and effect and shall not be affected by the illegal, invalid or unenforceable provision, and there shall be added automatically as part of this Agreement a provision as similar in its terms to such illegal, invalid or unenforceable provision as may be possible and be legal, valid and enforceable.

13.     Entire Agreement .    This Agreement constitutes the entire agreement and understanding between the parties, except to the extent that Executive may have ongoing restrictive covenants provided for in the Employment Agreement or elsewhere that survive the termination of his employment [such covenants will be identified with particularity] . The Executive has not relied on any oral statements that are not expressly stated in this Agreement.

[ Remainder of page intentionally left blank. Signature page follows. ]

    






IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.
 
 
 
 
LUMINEX CORPORATION
 
 
 
 
By:
 
 
Name:
 
 
Its:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nachum Shamir, individually


Signature Page to General Release Agreement by and between Luminex Corporation and Nachum Shamir


Exhibit 99.1



Luminex Corporation Announces Retirement of Patrick Balthrop, President and CEO
Nachum "Homi" Shamir to Become President and CEO Effective Immediately;
Balthrop Will Continue as Consultant to the Board Through April 14, 2015

Austin, Texas, Oct. 15, 2014 -- Luminex Corporation (NASDAQ: LMNX) today announced that Patrick J. Balthrop, Sr. has retired as President and CEO. The board of directors has named Nachum "Homi" Shamir as President and CEO. Mr. Balthrop has resigned as a director but will continue to serve the company and its shareholders as a consultant to the Board and Mr. Shamir, and will be assisting in the transition through April 14, 2015. Mr. Shamir is expected to be invited to join the board of directors.

On behalf of the Board of Directors, Wally Loewenbaum, Chairman, said, "The Board is excited to have a talented executive in Homi Shamir join the Company. Mr. Shamir brings a proven track record of global leadership and results. He is a high energy executive focused on delivering tangible results from energized employees. Together, we believe we will be able to continue to execute our company’s vision. The Board thanks Patrick Balthrop for his service in leading Luminex over the past decade. During his tenure as CEO, the company has grown from $30 million in revenue to well over $200 million, expanded internationally, built a strong portfolio and pipeline through organic investment and several acquisitions, and significantly increased profits while investing heavily in innovation, new product development and commercial expansion.”

Mr. Shamir most recently served as President and Chief Executive Officer at Given Imaging from 2006 until February 2014 when the company was acquired by Covidien plc in a transaction valued at approximately $1 billion. Under Mr. Shamir's leadership, Given Imaging broadened its product portfolio, organically and through acquisitions, significantly increased revenues and earnings and expanded its global commercial footprint. 

Prior to joining Given Imaging Ltd., Mr. Shamir served as Corporate Vice President of the Eastman Kodak Company and as the President of Eastman Kodak’s Transaction and Industrial Solutions. Mr. Shamir served over 10 years at Scitex Corporation where he had a track record of achievement and increasing responsibility, including serving as President and Chief Executive Officer from 2003-2004. Before joining Scitex, Mr. Shamir held senior management positions at various international companies mainly in the Asia Pacific region. Mr. Shamir holds a Bachelor of Science from the Hebrew University of Jerusalem and a Masters of Public Administration from Harvard University.

"I am honored to have the opportunity to join Luminex at this exciting time. The Company's financial strength, combined with a strong pipeline of highly differentiated products, an outstanding network of long term customers and partners and very talented dedicated team of employees worldwide, position us for accelerated growth and profitability,” said Mr. Shamir. “Our top priority will be to build a bright future in the tradition of market leadership and strong financial performance to enhance shareholder value.”

Mr. Balthrop commented, "I am grateful to have spent nearly 10 years leading this outstanding company. I could not be more proud of the growth, innovation and groundbreaking technologies that my talented and motivated Luminex colleagues around the world have delivered, especially during such a turbulent decade. It is my firm belief that 2014 is the right time for me to retire. First, the company has a strong foundation and bright future with sunny skies ahead. The Company is operationally very solid and positioned for continued success. And second, Homi Shamir is a rare and gifted business leader with deep experience in medical devices who has proven his ability to lead a company and build shareholder value. I could not be more pleased to hand the reins of Luminex to such a strong executive who will be able to take Luminex to the next level and beyond."






About Luminex Corporation 

Luminex is committed to applying its passion for innovation toward creating breakthrough solutions to improve health and advance science. The company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP® open-architecture multi-analyte platform,  MultiCode®  real-time polymerase chain reaction (PCR), and multiplex PCR-based technologies, that deliver cost-effective rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories, as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. Luminex is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, biodefense research and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology, please visit  http://www.luminexcorp.com .

Statements made in this release that express Luminex Corporation's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products, the Company's dependence on strategic partners for development, commercialization and distribution of products, concentration of the Company's revenue in a limited number of strategic partners, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle and bulk purchases of consumables, Luminex's ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, potential shortages of components, competition, the timing of regulatory approvals, the implementation, including any modification, of the Company's strategic operating plans, risks and uncertainties associated with implementing our acquisition strategy and the ability to integrate acquired companies or selected assets into our consolidated business operations, as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Contact:   
Luminex Corporate Contact: 
Harriss Currie 
Sr. Vice President, Finance and CFO 
hcurrie@luminexcorp.com
512.219.8020

Media: 
Mimi Torrington 
Director of Marketing Communications 
mtorrington@luminexcorp.com 
512.219.8020